EP2385829A1 - Composés pro-neurogéniques - Google Patents

Composés pro-neurogéniques

Info

Publication number
EP2385829A1
EP2385829A1 EP10711784A EP10711784A EP2385829A1 EP 2385829 A1 EP2385829 A1 EP 2385829A1 EP 10711784 A EP10711784 A EP 10711784A EP 10711784 A EP10711784 A EP 10711784A EP 2385829 A1 EP2385829 A1 EP 2385829A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
independently selected
carbazol
optionally substituted
propan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10711784A
Other languages
German (de)
English (en)
Other versions
EP2385829B1 (fr
Inventor
Steven L. Mcknight
Andrew A. Pieper
Joseph M. Ready
Jef De Brabander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of EP2385829A1 publication Critical patent/EP2385829A1/fr
Application granted granted Critical
Publication of EP2385829B1 publication Critical patent/EP2385829B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • This invention relates generally to the discovery of pro-neurogenic compounds capable of promoting neurogenesis and/or reducing neuronal cell death.
  • neuronal stem cells there are two major reservoirs of neuronal stem cells, one located in the subgranular zone (SGZ) of the hippocampal dentate gyrus and another in the subventricular zone (SVZ) (Gross, 2000).
  • SGZ subgranular zone
  • SVZ subventricular zone
  • Neural stem cells in the SVZ facilitate formation of new neurons that migrate rostrally to populate the olfactory bulb
  • neural stem cells in the SGZ produce neurons that integrate locally in the granular layer of the dentate gyrus, a region of the hippocampus that exhibits lifelong structural and functional plasticity.
  • the process of new neuron formation in the adult mouse brain can be influenced by environmental, chemical and genetic variables. As demonstrated by Gage and colleagues, neurogenesis in the adult mouse brain is enhanced when animals are exposed to an enriched environment (Kempermann et al., 1998) or able to exercise voluntarily (van Praag et al., 1999). More recently, anti-depressant drugs have been shown to enhance levels of adult neurogenesis in animals, including humans (Schmidt and Duman, 2007; Boldrini et al., 2009).
  • NPAS3 neuronal PAS domain protein 3
  • CNS central nervous system
  • This invention relates generally to compounds that promote the generation or the survival of existing neurons in the mammalian brain.
  • these compounds for the purpose of simplicity we refer to these compounds as being pro-neurogenic.
  • the compounds promote the generation or survival of neurons in the post-natal mammalian brain.
  • the compounds promote the survival, growth, development and/or function of neurons, particularly CNS, brain, cerebral, and hippocampal neurons.
  • the compounds stimulate post-natal hippocampal neurogenesis, which while not wishing to be bound by theory, is believed to represent a therapeutic target for a variety of neuropsychiatric and neurodegenerative diseases, including (but not limited to) schizophrenia,major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post- traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, and abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine, and cocaine.
  • the invention also features compositions (e.g., pharmaceutical compositions) that include such compounds as well as methods of making, identifying, and using such compounds. Other features and advantages are described in, or will be apparent from, the present specification and accompanying drawings.
  • methods for promoting post-natal mammalian neurogenesis in a subject in need thereof include administering to the subject an effective amount of a compound having formula (I) or a pharmaceutically acceptable salt thereof.
  • each of R 1 , R 2 , R 3 , and R 4 is independently selected from hydrogen, halo, hydroxyl, sulfhydryl, Ci-C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, Ci-C 6 alkyl, Ci-C 6 haloalkyl, cyano, -NH 2 , -NH(Ci-C 6 alkyl), -N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and nitro;
  • R and R' are defined according to (1), (2), (3), (4), or (5) below:
  • each of R 5 , R 6 , R 7 , and R 8 is independently selected from hydrogen, halo, hydroxyl, sulfhydryl, Ci-C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 halothioalkoxy, Ci-C 6 alkyl, Ci-C 6 haloalkyl, cyano, -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and nitro; OR
  • each of R and R' is, independently, hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl;
  • R and R' together with C 2 and C 3 , respectively, form a fused heterocyclic ring containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocyclic ring is optionally substituted with from 1-3 independently selected R a ; OR
  • R and R' together with C 2 and C 3 , respectively, form a fused heteroaryl ring containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl ring is optionally substituted with from 1-3 independently selected R b ;
  • R A1 and R A2 are independently selected from hydrogen, halo, C 1 -C 3 alkyl, or OR 9 ; or
  • heterocycloalkylene containing from 3-5 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heterocycloalkylene is (a) substituted with 1 oxo; and (b) is optionally further substituted with from 1-4 independently selected R a ;
  • heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 independently selected R b ; or
  • the aryl portion is optionally substituted with from 1-4 independently selected R b , and
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;
  • the aryl portion from is optionally substituted with from 1-4 independently selected R b , and
  • heterocyclyl portion is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ; or
  • (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ; or
  • heteroarylcycloalkyl containing from 8-14 ring atoms, wherein: (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;
  • R 9 is hydrogen; or Ci-C 3 alkyl that is optionally substituted with hydroxyl or C 1 -
  • each of R 10 and R 11 is independently selected from the substituents delineated collectively in (a) through (k) below:
  • heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;
  • the aryl portion is optionally substituted with from 1-4 independently selected R b , and
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;
  • the aryl portion from is optionally substituted with from 1-4 independently selected R b , and
  • (2) from 1-2 of the ring atoms of the heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ;
  • (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • heterocyclyl portion is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ;
  • (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;
  • R 12 is:
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;
  • the aryl portion from is optionally substituted with from 1-4 independently selected R b , and
  • heterocyclyl portion is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ; or
  • (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ; or
  • (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ; (i) C 6 -Ci O aryl that is optionally substituted with from 1-4 R b ; or (ii) heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ; (iii) C 8 -C 14 arylcycloalkyl, wherein:
  • the aryl portion is optionally substituted with from 1-4 independently selected R b , and
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;
  • the aryl portion from is optionally substituted with from 1-4 independently selected R b , and
  • heterocyclyl portion is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ; or
  • (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • heterocyclyl portion is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ; or
  • (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;
  • R b at each occurrence is independently selected from the substituents delineated in (aa) through (dd) below:
  • (cc) C 3 -C 6 cycloalkyl or heterocyclyl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms of the heterocyclyl is independently selected from N, NH, N(C 1 -C 6 alkyl), NC(O)(C 1 -C 6 alkyl), O, and S; and wherein each of said phenyl and heterocyclyl is optionally substituted with from 1-3 independently selected R a ; and
  • R c at each occurrence is, independently selected from halo, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, Ci-C 6 haloalkoxy, Ci-C 6 thiohaloalkoxy, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and cyano;
  • R d at each occurrence is, independently selected from hydroxyl, C 1 -C 6 alkoxy, Ci-C 6 thioalkoxy, Ci-C 6 haloalkoxy, Ci-C 6 thiohaloalkoxy, Ci-C 6 alkyl, Ci-C 6 haloalkyl, -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and cyano; and
  • R e at each occurrence is, independently selected from hydroxyl, C 1 -C 6 alkoxy; C 1 - C 6 thioalkoxy; Ci-C 6 haloalkoxy; Ci-C 6 thiohaloalkoxy; -NH 2 ; -NH(Ci-C 6 alkyl); N(C 1 - C 6 alkyl) 2 ; -NHC(O)(Ci-C 6 alkyl); cyano; -C(O)H; -C(O)(Ci-C 6 alkyl); -C(O)(Ci-C 6 haloalkyl); C(O)OH; -C(O)O(C 1 -C 6 alkyl); -C(O)NH 2 ; -C(O)NH(C 1 -C 6 alkyl); C(O)N(Ci-C 6 alkyl) 2 ; -SO 2 (CrC 6 alkyl); -SO 2 NH 2 ;
  • one or more of (A), (B), or (C) apply.
  • each of L 1 and L 2 must be Ci-C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c when A is CH 2 ; or
  • Z must be other than heteroaryl containing from 5-14 (e.g., 5-6 or 6)ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 - C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 independently selected R b ; e.g., other than substituted pyridyl, e.g., other than pyridyl substituted with C 1 -C 3 alkyl (e.g., CH 3 ), e.g., other than 2 or 6-methylpyridyl.
  • each of R 10 and R 11 cannot be optionally substituted naphthyl (e.g., each of R 10 and R 11 cannot be unsubstituted naphthyl).
  • each of R 10 and R 11 is other than optionally substituted naphthyl (e.g., unsubstituted naphthyl) when R and R' are defined according to definitions (1), (2), and (4); and
  • A is CR ⁇ R ⁇ (e.g., CHOR 9 , e.g., CHOH), and each of L 1 and L 2 is C 1 -C 3 alkylene (e.g., each of L 1 and L 2 is CH 2 ).
  • R 12 and/or R 13 cannot be substituted phenyl.
  • R 12 and/or R 13 cannot be substituted phenyl.
  • R , 13 cannot be substituted phenyl when R and R' are defined according to definition (1); and A is CR A1 R A2 (e.g., CHOR 9 , e.g., CHOH), and each of L 1 and L 2 is Ci-C 3 alkylene (e.g., each of L 1 and L 2 is CH 2 ).
  • (A), (B), or (C) applies. In other embodiments, (A) and (B); or (A) and (C); or (B) and (C) applies. In still other embodiments, (A), (B), or (C) apply.
  • methods for promoting post-natal mammalian neurogenesis in a subject in need thereof include administering to the subject an effective amount of a compound having formula (I) or a pharmaceutically acceptable salt thereof, in which R and R' together with C 2 and C 3 , respectively, form a fused phenyl ring having formula (II):
  • R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , A, and Z can be as defined anywhere herein.
  • (A), (B), or (C) applies. In other embodiments, (A) and (B); or (A) and (C); or (B) and (C) applies. In still other embodiments, (A), (B), or (C) apply.
  • methods for promoting post-natal mammalian neurogenesis in a subject in need thereof include administering to the subject an effective amount of a compound having formula (I) or a pharmaceutically acceptable salt thereof, in which: each of L 1 and L 2 is CH 2 .;
  • R A is CR ⁇ R ⁇ , wherein one of R A1 and R A2 is OR 9 , and the other is hydrogen.
  • Z is -NR 10 R 11 ; and each of R 10 and R 11 is independently selected from
  • compositions e.g., a pharmaceutical composition
  • a pharmaceutical composition which includes a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein and a pharmaceutically acceptable carrier.
  • the compositions can include an effective amount of the compound or salt.
  • the compositions can further include one or more additional therapeutic agents.
  • antidepressant medications including selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and other antidepressant medications including but not limited to venlafaxine, nefazadone, bupropion, mirtazapine, lithium and trazodone
  • acetylcholinesterase inhibitors including but not limited to Aricept, Reminyl, and Exelon.
  • dosage forms are featured, which includes from about 0.05 milligrams to about 2,000 milligrams (e.g., from about 0.1 milligrams to about 1,000 milligrams, from about 0.1 milligrams to about 500 milligrams, from about 0.1 milligrams to about 250 milligrams, from about 0.1 milligrams to about 100 milligrams, from about 0.1 milligrams to about 50 milligrams, or from about 0.1 milligrams to about 25 milligrams) of a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein.
  • the dosage forms can further include a pharmaceutically acceptable carrier and/or an additional therapeutic agent.
  • the compounds of formula (I) themselves (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein are featured.
  • any of the formula (I) compounds specifically described herein are featured.
  • compounds of formula (III) are featured in which:
  • R A is CR ⁇ R* 2 , in which each of R A1 and R ⁇ is, independently, hydrogen, halo, or Ci-C 3 alkyl; or
  • R A is CR ⁇ R ⁇ , in which one of R A1 and R ⁇ is halo (e.g., fluoro), and the other of R A1 and R ⁇ is, independently, hydrogen, halo, or C 1 -C 3 alkyl (e.g., hydrogen); or
  • R A is CR ⁇ R ⁇ , in which one of R A1 and R ⁇ is halo (e.g., fluoro), and the other of R A1 and R ⁇ is hydrogen; and
  • R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , and Z can be as defined anywhere herein; or a salt (e.g., pharmaceutically acceptable salt) thereof.
  • (B) and/or (C) applies.
  • R A1 and R ⁇ can be OR 9 .
  • the other of R A1 and R A2 can be as defined anywhere herein; e.g., the other of R A1 and R ⁇ can be hydrogen or Ci-C 3 alkyl.
  • one of R A1 and R ⁇ can be OR 9 , and the other of R A1 and R ⁇ is hydrogen.
  • R 9 can be hydrogen; and
  • R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , and Z can be as defined anywhere herein; or a salt (e.g., pharmaceutically acceptable salt) thereof.
  • one or more of the following apply, e.g., when A is CHOH and each of R 3 and R 6 is CH 3 ; and/or each of R 3 and R 6 is bromo; and/or each of R 3 and R 6 is chloro; and/or one of R 3 and R 6 is CH 3 (e.g., R 6 ), and the other is bromo (e.g., R 3 ); each of R 10 and R 11 is other than hydrogen; each of R 10 and R 11 is hydrogen; one of R 10 and R 11 is heteroaryl as defined anywhere herein;
  • L 1 and/or L 2 is C 2 -C 3 alkylene (optionally substituted);
  • (B) and/or (C) applies.
  • compounds of formula (III) are featured in which Z is other than NR 10 R 11 ; and R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , Z, and A can be as defined anywhere herein; or a salt (e.g., pharmaceutically acceptable salt) thereof.
  • (B) and/or (C) applies.
  • compounds of formula (III) are featured in which Z is -OR 12 and/or -S(O) n R 13 ; and R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , and A can be as defined anywhere herein; or a salt (e.g., pharmaceutically acceptable salt) thereof.
  • (B) and/or (C) applies.
  • This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting neurons from death with a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein.
  • a compound of formula (I) and/or a compound of any of the other formulae described herein
  • a salt e.g., a pharmaceutically acceptable salt
  • methods of promoting the generation of neurons are featured.
  • methods of promoting the survival, growth, development and/or function of neurons, particularly CNS, brain, cerebral, and hippocampal neurons are featured.
  • methods of stimulating post-natal hippocampal neurogenesis are featured.
  • such methods can include in vitro methods, e.g., contacting a sample (e.g., a cell or tissue) with a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein.
  • the methods can include administering a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein to a subject (e.g., a mammal, such as a human).
  • this invention includes and features methods of screening for (thereby identifying) compounds that stimulate neurogenesis (e.g., postnatal neurogenesis, e.g., post-natal hippocampal neurogenesis) or protect newborn neurons from cell death.
  • neurogenesis e.g., postnatal neurogenesis, e.g., post-natal hippocampal neurogenesis
  • protect newborn neurons from cell death e.g., such as those described in the Examples section.
  • methods for treating e.g., controlling, relieving, ameliorating, alleviating, or slowing the progression of
  • methods for preventing e.g., delaying the onset of or reducing the risk of developing
  • the methods include administering to the subject an effective amount of a compound a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein to the subject.
  • a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein in the preparation of, or for use as, a medicament for the treatment (e.g., controlling, relieving, ameliorating, alleviating, or slowing the progression of) or prevention (e.g., delaying the onset of or reducing the risk of developing) of one or more diseases, disorders, or conditions caused by, or associated with, insufficient (e.g., aberrant) neurogenesis or unwanted neuronal cell death is featured.
  • a salt e.g., a pharmaceutically acceptable salt
  • the one or more diseases, disorders, or conditions can include neuropathies, nerve trauma, and neurodegenerative diseases.
  • the one or more diseases, disorders, or conditions can be diseases, disorders, or conditions caused by, or associated with insufficient neurogenesis (e.g., aberrant hippocampal neurogenesis) as is believed to occur in neuropsychiatric diseases, or aberrant neuronal cell death as is believed to occur in neurodegenerative diseases.
  • insufficient neurogenesis e.g., aberrant hippocampal neurogenesis
  • Examples of the one or more diseases, disorders, or conditions include, but are not limited to, schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, posttraumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, and abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine, and cocaine.
  • neuro-active drugs such as alcohol, opiates, methamphetamine, phencyclidine, and cocaine.
  • the subject can be a subject in need thereof (e.g., a subject identified as being in need of such treatment, such as a subject having, or at risk of having, one or more of the diseases or conditions described herein). Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
  • the subject can be a mammal. In certain embodiments, the subject can be a human.
  • methods of making the compounds described herein include taking any one of the intermediate compounds described herein and reacting it with one or more chemical reagents in one or more steps to produce a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein.
  • compounds in which A is CHOH, and each of L 1 and L 2 is C 1 -C 3 alkylene can be converted to compounds in which A is C(O), and each of L 1 and L 2 is C 1 -C 3 alkylene (e.g., each of L 1 and L 2 is CH 2 ) that is substituted with Ci-C 6 thioalkoxy (e.g., -SCH 3 ).
  • the methods include contacting the starting material with an oxidizing agent sulfur trioxide pyridine complex (see, e.g., Example 7a and 7b).
  • methods of making the pharmaceutical compositions described herein are featured.
  • the methods include taking any one or more of the compounds of formula (I) (and/or compounds of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein, and mixing said compound(s) with one or more pharmaceutically acceptable carriers.
  • kits for the treatment e.g., controlling, relieving, ameliorating, alleviating, or slowing the progression of
  • prevention e.g., delaying the onset of or reducing the risk of developing
  • the kits include (i) a compound of formula (I) (and/or compounds of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein; and (ii) instructions that include a direction to administer said compound to a subject (e.g., a patient).
  • Embodiments can include, for example, any one or more of the following features.
  • R can be selected from halo, hydroxyl, sulfhydryl, Ci-C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and nitro.
  • R 3 can be halo (e.g., bromo).
  • each of R 1 , R 2 , and R 4 can be hydrogen.
  • L 1 can be C 1 -C 3 straight chain alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • L 1 can be CH 2 .
  • L can be C 1 -C 3 straight chain alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • L can be CH 2 .
  • Each of L 1 and L 2 can be, independently, C 1 -C 3 straight chain alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • each of L 1 and L 2 can be CH 2 .
  • R A can be CR A1 R A2 , in which each of R A1 and R A2 is, independently, hydrogen, halo, Ci-C 3 alkyl, or OR 9 .
  • R A can be CR A1 R A2 , in which each of R A1 and R A2 is, independently, hydrogen, halo, or Ci-C 3 alkyl.
  • A can be CR A1 R A2 , in which one of R A1 and R ⁇ is halo (e.g., fluoro), and the other of R A1 and R A2 is, independently, hydrogen, halo, or C 1 -C 3 alkyl (e.g., hydrogen).
  • A can be CR A1 R A2 , in which one of R A1 and R ⁇ is halo (e.g., fluoro), and the other of R A1 and R A2 is hydrogen.
  • R A1 and R ⁇ can be halo or OR 9 , and the other is hydrogen.
  • R A1 and R ⁇ can be OR 9 .
  • the other of R A1 and R A2 can be as defined anywhere herein; e.g., the other of R A1 and R ⁇ can be hydrogen or C 1 -C 3 alkyl.
  • one of R A1 and R ⁇ can be OR 9 , and the other of R A1 and R ⁇ is hydrogen.
  • R 9 can be hydrogen.
  • R A1 and R ⁇ can be halo.
  • the other of R A1 and R A2 can be as defined anywhere herein; e.g., the other of R A1 and R ⁇ can be hydrogen, C 1 -C 3 alkyl, or halo.
  • one of R A1 and R ⁇ can be halo (e.g., fluoro), and the other of R A1 and R A2 is hydrogen.
  • the carbon attached to R A1 and R A2 can have the R configuration.
  • the carbon attached to R A1 and R A2 can have the S configuration.
  • Each of L 1 and L 2 is, independently, Ci -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • each of L 1 and L 2 can be CH 2 .
  • Z can be -NR 10 R 11 .
  • R 10 and R 11 can be C 6 -Ci O aryl that is optionally substituted with from 1-4
  • R 10 and R 11 can be C 6 -Ci O aryl that is optionally substituted with from 1-4 R b , and the other is hydrogen or C 1 -C 6 alkyl.
  • R 10 and R 11 can be C 6 -Ci O aryl that is optionally substituted with from 1-4 R b , and the other is hydrogen.
  • one of R 10 and R 11 can be unsubstituted phenyl, and the other is hydrogen.
  • one of R 10 and R 11 can be phenyl that is substituted with 1 R b , and the other is hydrogen.
  • R b can be C 1 -C 6 alkoxy (e.g., OCH 3 ).
  • one of R 10 and R 11 can be 3-methoxyphenyl, and the other is hydrogen.
  • Z can be -OR 12 .
  • R 12 can be C 1 -C 6 alkyl or C 1 -C 6 haloalkyl, each of which is optionally substituted with from 1-3 R c .
  • R 12 can be C 6 -Ci O aryl that is optionally substituted with from 1-4 R b .
  • R 12 can be unsubstituted phenyl.
  • Z can be -S(O) n R 13 , in which n can be 0, 1, or 2.
  • R 13 can be C 6 -Ci O aryl that is optionally substituted with from 1-4 R b .
  • R 13 can be unsubstituted phenyl.
  • Z can be heterocycloalkenyl containing from 5-6 ring atoms, wherein from 1-3 of the ring atoms is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocycloalkenyl is optionally substituted with from 1-4 independently selected R a .
  • R can be selected from halo, hydroxyl, sulfhydryl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and nitro.
  • R 6 can be halo (e.g., bromo).
  • each of R 5 , R 7 , and R 8 can be hydrogen. Any one or more of the R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , A, and Z embodiments described herein can be combined with any one or more of the R 5 , R 6 , R 7 , and R 8 embodiments described herein.
  • Each of L 1 and L 2 can be CH 2 .
  • A can be CR A1 R A2 , wherein one of R A1 and R ⁇ is OR 9 , and the other is hydrogen.
  • Z is -NR 10 R 11 ; and each of R 10 and R 11 can be independently selected from: (a) hydrogen; (b) C 6 -Ci O aryl that is optionally substituted with from 1-4 R b ; (d) Ci-C 6 alkyl or Ci-C 6 haloalkyl, each of which is optionally substituted with from 1-3 R d ; and (f) C 2 -C 6 alkenyl or C 2 -C 6 alkynyl.
  • R 3 and R 6 can be halo (e.g., bromo); and each of R 1 , R 2 , R 4 , R 5 , R 7 , and R 8 can be hydrogen.
  • R 9 can be hydrogen.
  • One of R 10 and R 11 can be C 6 -Ci O aryl that is optionally substituted with from 1-4 R b , and the other is hydrogen.
  • One of R 10 and R 11 can be unsubstituted phenyl, and the other is hydrogen.
  • One of R 10 and R 11 can be phenyl that is substituted with 1 R b , and the other is hydrogen.
  • R b can be Ci-C 6 alkoxy (e.g., OCH 3 ).
  • One of R 10 and R 11 can be 3-methoxyphenyl, and the other is hydrogen.
  • Each of L 1 and L 2 is CH 2 .
  • A is CR A1 R A2 , wherein one of R A1 and R ⁇ is OR 9 , and the other is hydrogen.
  • Z is -NR 10 R 11 ; and each of R 10 and R 11 is independently selected from: (a) hydrogen; (b) C 6 -Ci O aryl that is optionally substituted with from 1-4 R b ; (d) Ci-C 6 alkyl or C 1 -C 6 haloalkyl, each of which is optionally substituted with from 1-3 R d ; and (f) C 2 -C 6 alkenyl or C 2 -C 6 alkynyl.
  • Embodiment can include one or more of the following fearures.
  • R 3 and R 6 is halo (e.g., bromo); and each of R 1 , R 2 , R 4 , R 5 , R 7 , and R 8 is hydrogen.
  • R 9 can be hydrogen.
  • One of R 10 and R 11 can be C 6 -Ci O aryl that is optionally substituted with from 1-4 R b , and the other is hydrogen.
  • One of R 10 and R 11 can be unsubstituted phenyl, and the other is hydrogen.
  • One of R 10 and R 11 can be phenyl that is substituted with 1 R b , and the other is hydrogen.
  • R b can be Ci-C 6 alkoxy (e.g., OCH 3 ).
  • One of R 10 and R 11 can be 3-methoxyphenyl, and the other is hydrogen.
  • (A), (B), or (C) applies. In other embodiments, (A) and (B); or (A) and (C); or (B) and (C) applies. In still other embodiments, (A), (B), or (C) apply.
  • Each of R and R' can be, independently, hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
  • Each of R and R' can be, independently, Ci-C 6 alkyl (e.g., each of R and R' can be CH 3 ).
  • Each of R and R' can be hydrogen.
  • the compound having formula (I) can include any one or more of or be selected from: i?-l-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol; 5 r -l-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol; l-(3,6-dibromo-9H-carbazol-9-yl)-3-(2-iminopyridin-l(2H)-yl)propan-2-ol; l-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylthio)propan-2-ol;
  • the compound having formula (I) can be l-(3,6-dibromo- 9H-carbazol-9-yl)-3-(phenylamino)propan-2-ol; or a salt (e.g., a pharmaceutically acceptable salt) thereof.
  • the compound having formula (I) can be R-l-(3,6- Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol; or a salt (e.g., a pharmaceutically acceptable salt) thereof.
  • i?-l-(3,6-Dibromo-9H- carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol or a salt (e.g., a pharmaceutically acceptable salt) thereof can be substantially free of (e.g., contains less than about 5% of, less than about 2% of, less than about 1%, less than about 0.5% of) S-I-Q, 6-Dibromo- 9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol or a salt (e.g., a pharmaceutically acceptable salt) thereof.
  • the compound having formula (I) can be S-l-(3,6- Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol; or a salt (e.g., a pharmaceutically acceptable salt) thereof.
  • 5 r -l-(3,6-Dibromo-9H- carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol or a salt (e.g., a pharmaceutically acceptable salt) thereof can be substantially free of (e.g., contains less than about 5% of, less than about 2% of, less than about 1%, less than about 0.5% of) i?-l-(3,6-Dibromo- 9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol or a salt (e.g., a pharmaceutically acceptable salt) thereof.
  • the compound having formula (I) can be the (+) (dextrorotatory) enantiomer of l-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3- methoxyphenylamino)-propan-2-ol as described herein or a salt (e.g., a pharmaceutically acceptable salt) thereof. See, e.g., Example Ia and Ib.
  • the (+) (dextrorotatory) enantiomer of l-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3- methoxyphenylamino)-propan-2-ol as described herein or a salt (e.g., a pharmaceutically acceptable salt) thereof can be substantially free of (e.g., contains less than about 5% of, less than about 2% of, less than about 1%, less than about 0.5% of) the (-) (levorotatory) enantiomer of l-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2- ol as described herein or a salt (e.g., a pharmaceutically acceptable salt) thereof.
  • the compound having formula (I) can be the (-) (levorotatory) enantiomer of l-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3- methoxyphenylamino)-propan-2-ol as described herein or a salt (e.g., a pharmaceutically acceptable salt) thereof. See, e.g., Example Ia and Ib.
  • the (-) (levorotatory) enantiomer of l-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3- methoxyphenylamino)-propan-2-ol as described herein or a salt (e.g., a pharmaceutically acceptable salt) thereof can be substantially free of (e.g., contains less than about 5% of, less than about 2% of, less than about 1%, less than about 0.5% of) the (+) (dextrorotatory) enantiomer of l-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3- methoxyphenylamino)-propan-2-ol as described herein or a salt (e.g., a pharmaceutically acceptable salt) thereof.
  • the methods can further include detecting a resultant neurotrophism (e.g., neurogenesis; and/or determining that the patient has aberrant neurotrophism, particularly aberrant neurogenesis, particularly aberrant hippocampal neurogenesis, or a disease or disorder associated therewith, particularly by detecting and/or diagnosing the same.
  • a resultant neurotrophism e.g., neurogenesis
  • determining that the patient has aberrant neurotrophism, particularly aberrant neurogenesis, particularly aberrant hippocampal neurogenesis, or a disease or disorder associated therewith particularly by detecting and/or diagnosing the same.
  • the methods can further include detecting a resultant neurotrophism.
  • the methods can further include detecting determining that the subject has aberrant neurogenesis or death of neurons or a disease or disorder associated therewith, by detecting the same in said subject.
  • the methods can further include detecting a resultant hippocampal neurogenesis.
  • the disease, disorder, or condition can be a neuropsychiatric and neurodegenerative disease, including (but not limited to) schizophrenia,major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, and abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine, and cocaine.
  • neuro-active drugs such as alcohol, opiates, methamphetamine, phencyclidine, and cocaine.
  • the compounds having formula (I) or a salt (e.g., a pharmaceutically acceptable salt) thereof provide at least about 27 (X10E-06) BrdU+ cells / mm 3 dentate gyrus when evaluated in the assay described in conjunction with Table 1 (i.e., evaluated for pro-neurogenic efficacy / neuroprotection in our standard in vivo assay at 10 ⁇ M concentration in four 12 week old adult male C57/B16 mice..
  • the compounds having formula (I) or a salt (e.g., a pharmaceutically acceptable salt) thereof provide at least about 19 (X10E-06) BrdU+ cells / mm 3 dentate gyrus when evaluated in the assay described in conjunction with Table 1.
  • the compounds having formula (I) or a salt (e.g., a pharmaceutically acceptable salt) thereof provide from about 18 to about 30 (e.g., 18-27, 19-26, 20-25, 27-30, 27-29) (X10E-06) BrdU+ cells / mm 3 dentate gyrus when evaluated in the assay described in conjunction with Table 1.
  • the compounds having formula (I) or a salt (e.g., a pharmaceutically acceptable salt) thereof provide from about 18 to about 26 (e.g., 19-26, 20-25) (X10E-06) BrdU+ cells / mm 3 dentate gyrus when evaluated in the assay described in conjunction with Table 1.
  • the compounds having formula (I) or a salt (e.g., a pharmaceutically acceptable salt) thereof provide from about 27 to about 30 (e.g., 27-29) (X10E-06) BrdU+ cells / mm dentate gyrus when evaluated in the assay described in conjunction with Table 1.
  • any compound, composition, or method described herein can also include any one or more of the other features delineated in the detailed description and/or in the claims.
  • an effective amount refers to an amount of a compound that confers a therapeutic effect (e.g., treats, e.g., controls, relieves, ameliorates, alleviates, or slows the progression of; or prevents, e.g., delays the onset of or reduces the risk of developing, a disease, disorder, or condition or symptoms thereof) on the treated subject.
  • the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
  • An effective amount of the compound described above may range from about 0.01 mg/kg to about 1000 mg/kg, (e.g., from about 0.1 mg/kg to about 100 mg/kg, from about 1 mg/kg to about 100 mg/kg). Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.
  • halo or halogen refers to any radical of fluorine, chlorine, bromine or iodine.
  • substituent (radical) prefix names are derived from the parent hydride by either (i) replacing the "ane” in the parent hydride with the suffixes "yl,” “diyl,” “triyl,” “tetrayl,” etc.; or (ii) replacing the "e” in the parent hydride with the suffixes "yl,” “diyl,” “triyl,” “tetrayl,” etc. (here the atom(s) with the free valence, when specified, is (are) given numbers as low as is consistent with any established numbering of the parent hydride).
  • Accepted contracted names e.g., adamantyl, naphthyl, anthryl, phenanthryl, furyl, pyridyl, isoquinolyl, quinolyl, and piperidyl, and trivial names, e.g., vinyl, allyl, phenyl, and thienyl are also used herein throughout.
  • Conventional numbering/lettering systems are also adhered to for substituent numbering and the nomenclature of fused, bicyclic, tricyclic, polycyclic rings.
  • radicals, substituents, and ranges are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.
  • alkyl, alkoxy, alkenyl, and the like denote both straight and branched groups.
  • alkyl refers to a saturated hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms.
  • Ci-C 6 alkyl indicates that the group may have from 1 to 6 (inclusive) carbon atoms in it. Any atom can be optionally substituted, e.g., by one or more subsitutents.
  • alkyl groups include without limitation methyl, ethyl, w-propyl, zsopropyl, and tert-butyl.
  • straight chain C n _ m alkylene refers to a non-branched divalent alkyl linking group having n to m carbon atoms. Any atom can be optionally substituted, e.g., by one or more subsitutents. Examples include methylene (i.e., -CH 2 -).
  • haloalkyl refers to an alkyl group, in which at least one hydrogen atom is replaced by halo. In some embodiments, more than one hydrogen atom (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 ) are replaced by halo. In these embodiments, the hydrogen atoms can each be replaced by the same halogen (e.g., fluoro) or the hydrogen atoms can be replaced by a combination of different halogens (e.g., fluoro and chloro).
  • Haloalkyl also includes alkyl moieties in which all hydrogens have been replaced by halo (sometimes referred to herein as perhaloalkyl, e.g., perfluoroalkyl, such as trifluoromethyl). Any atom can be optionally substituted, e.g., by one or more substituents.
  • alkoxy refers to a group of formula -O(alkyl).
  • Alkoxy can be, for example, methoxy (-OCH 3 ), ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 2-pentoxy, 3-pentoxy, or hexyloxy.
  • thioalkoxy refers to a group of formula -S(alkyl).
  • haloalkoxy and thioalkoxy refer to -O(haloalkyl) and -S(haloalkyl), respectively.
  • sulfhydryl refers to -SH.
  • hydroxyl employed alone or in combination with other terms, refers to a group of formula -OH.
  • aralkyl refers to an alkyl moiety in which an alkyl hydrogen atom is replaced by an aryl group. One of the carbons of the alkyl moiety serves as the point of attachment of the aralkyl group to another moiety. Any ring or chain atom can be optionally substituted e.g., by one or more substituents.
  • aralkyl include benzyl, 2-phenylethyl, and 3-phenylpropyl groups.
  • alkenyl refers to a straight or branched hydrocarbon chain containing the indicated number of carbon atoms and having one or more carbon-carbon double bonds. Any atom can be optionally substituted, e.g., by one or more substituents. Alkenyl groups can include, e.g., vinyl, allyl, 1-butenyl, and 2-hexenyl. One of the double bond carbons can optionally be the point of attachment of the alkenyl substituent.
  • alkynyl refers to a straight or branched hydrocarbon chain containing the indicated number of carbon atoms and having one or more carbon-carbon triple bonds.
  • Alkynyl groups can be optionally substituted, e.g., by one or more substituents.
  • Alkynyl groups can include, e.g., ethynyl, propargyl, and 3-hexynyl.
  • One of the triple bond carbons can optionally be the point of attachment of the alkynyl substituent.
  • heterocyclyl refers to a fully saturated monocyclic, bicyclic, tricyclic or other polycyclic ring system having one or more constituent heteroatom ring atoms independently selected from O, N (it is understood that one or two additional groups may be present to complete the nitrogen valence and/or form a salt), or S.
  • the heteroatom or ring carbon can be the point of attachment of the heterocyclyl substituent to another moiety. Any atom can be optionally substituted, e.g., by one or more substituents.
  • Heterocyclyl groups can include, e.g., tetrahydrofuryl, tetrahydropyranyl, piperidyl (piperidino), piperazinyl, morpholinyl (morpholino), pyrrolinyl, and pyrrolidinyl.
  • heterocycloalkenyl refers to partially unsaturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups having one or more (e.g., 1-4) heteroatom ring atoms independently selected from O, N (it is understood that one or two additional groups may be present to complete the nitrogen valence and/or form a salt), or S.
  • a ring carbon (e.g., saturated or unsaturated) or heteroatom can be the point of attachment of the heterocycloalkenyl substituent. Any atom can be optionally substituted, e.g., by one or more substituents.
  • Heterocycloalkenyl groups can include, e.g., dihydropyridyl, tetrahydropyridyl, dihydropyranyl, 4,5-dihydrooxazolyl, 4,5- dihydro-lH-imidazolyl, 1,2,5,6-tetrahydro-pyrimidinyl, and 5,6-dihydro-2H- [l,3]oxazinyl.
  • cycloalkyl refers to a fully saturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups. Any atom can be optionally substituted, e.g., by one or more substituents.
  • Cycloalkyl moieties can include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, and norbornyl (bicycle[2.2.1]heptyl).
  • cycloalkenyl refers to partially unsaturated monocyclic, bicyclic, tricyclic, or other polycyclic hydrocarbon groups.
  • a ring carbon e.g., saturated or unsaturated is the point of attachment of the cycloalkenyl substituent. Any atom can be optionally substituted e.g., by one or more substituents.
  • Cycloalkenyl moieties can include, e.g., cyclohexenyl, cyclohexadienyl, or norbornenyl.
  • cycloalkylene refers to a divalent monocyclic cycloalkyl group having the indicated number of ring atoms.
  • heterocycloalkylene refers to a divalent monocyclic heterocyclyl group having the indicated number of ring atoms.
  • aryl refers to an aromatic monocyclic, bicyclic (2 fused rings), or tricyclic (3 fused rings), or polycyclic (> 3 fused rings) hydrocarbon ring system.
  • One or more ring atoms can be optionally substituted, e.g., by one or more substituents.
  • Aryl moieties include, e.g., phenyl and naphthyl.
  • heteroaryl refers to an aromatic monocyclic, bicyclic (2 fused rings), tricyclic (3 fused rings), or polycyclic (> 3 fused rings) hydrocarbon groups having one or more heteroatom ring atoms independently selected from O, N (it is understood that one or two additional groups may be present to complete the nitrogen valence and/or form a salt), or S.
  • One or more ring atoms can be optionally substituted, e.g., by one or more substituents.
  • heteroaryl groups include, but are not limited to, 2H-pyrrolyl, 3H- indolyl, 4H-quinolizinyl, acridinyl, benzo[b]thienyl, benzothiazolyl, ⁇ -carbolinyl, carbazolyl, coumarinyl, chromenyl, cinnolinyl, dibenzo[b,d]furanyl, furazanyl, furyl, imidazolyl, imidizolyl, indazolyl, indolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxazolyl, perimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phen
  • arylcycloalkyl and arylheterocyclyl refer to bicyclic, tricyclic, or other polycyclic ring systems that include an aryl ring fused to a cycloalkyl and heterocyclyl, respectively.
  • heteroarylheterocyclyl and “heteroarylcycloalkyl” refer to bicyclic, tricyclic, or other polycyclic ring systems that include a heteroaryl ring fused to a heterocyclyl and cycloalkyl, respectively. Any atom can be substituted, e.g., by one or more substituents.
  • arylcycloalkyl can include indanyl; arylheterocyclyl can include 2,3-dihydrobenzofuryl, 1,2,3,4- tetrahydroisoquinolyl, and 2,2-dimethylchromanyl.
  • oxo refers to double bonded oxygen when a substituent on carbon.
  • oxo is a substituent on nitrogen or sulfur, it is understood that the resultant groups has the structures N ⁇ O ⁇ and S(O) and SO 2 , respectively.
  • cyano employed alone or in combination with other terms, refers to a group of formula -CN, wherein the carbon and nitrogen atoms are bound together by a triple bond.
  • substituted refers to a group “substituted” on, e.g., an alkyl, haloalkyl, cycloalkyl, heterocyclyl, heterocycloalkenyl, cycloalkenyl, aryl, or heteroaryl group at any atom of that group.
  • the substituent(s) on a group are independently any one single, or any combination of two or more of the permissible atoms or groups of atoms delineated for that substituent.
  • a substituent may itself be substituted with any one of the above substituents.
  • the phrase "optionally substituted” means unsubstituted (e.g., substituted with a H) or substituted.
  • substituted means that a hydrogen atom is removed and replaced by a substitutent. It is understood that substitution at a given atom is limited by valency.
  • Descriptors such as "C 6 -Ci O aryl that is optionally substituted with from 1-4 independently selected R b " (and the like) is intended to include both an unsubstituted C 6 - Cio aryl group and a C 6 -CiO aryl group that is substituted with from 1-4 independently selected R b .
  • the use of a substituent (radical) prefix names such as alkyl without the modifier "optionally substituted” or “substituted” is understood to mean that the particular substituent is unsubstituted.
  • haloalkyl without the modifier "optionally substituted” or “substituted” is still understood to mean an alkyl group, in which at least one hydrogen atom is replaced by halo.
  • R b can be as defined in any one, two, three, or all of (aa) through (dd).
  • R b can be as defined in (aa) and (bb) or combinations thereof.
  • Cy is a saturated, partially unsaturated or aromatic carbocyclic or heterocyclic ring system
  • R e is understood to include each of the rings systems defined above (e.g., Cy can be coumarinyl or the ring component of biotin optionally substituted as defined anywhere herein).
  • Figure 1 Pulse-chase analysis of BrdU-labeling identified magnitude and timing of cell death following birth of new neurons in the dentate gyrus. 12 week old wild type male C57/B6 mice were individually housed without access to running wheels and injected on day 0 with BrdU (50 mg/kg, Lp.). Neural precursor cell proliferation in the dentate gyrus (DG) subgranular zone (SGZ) and granular layer (GL) was subsequently monitored through immunohistochemistry for BrdU on days 1, 5, 10, 15, 20, and 25 days post- injection.
  • DG dentate gyrus
  • SGZ subgranular zone
  • GL granular layer
  • mice Four mice were evaluated at each time point, and 25-30 adjacent coronal sections through the hippocampus (progressing posteriorly from the point where the suprapyramidal and infrapyramidal blades are joined at the crest region and the dentate gyrus is oriented horizontally beneath the corpus callosum) from each mouse were examined.
  • days 1 and 5 almost 100% of BrdU-positive cells within the DG were localized in the SGZ.
  • the total number of cells decreased approximately 40% between days 1 and 5, in accordance with the appearance of apoptotic cell bodies in the SGZ.
  • day 10 some BrdU positive cells had migrated into the GL, with no significant change in total number of BrdU-positive cells in the DG.
  • FIG. 2 Surgical placement of cannula and pumps did not affect hippocampal neurogenesis or survival of newborn neurons on the contralateral side of the brain.
  • FIG. 3 Ectopic incorporation of BrdU served to eliminate molecules from further consideration. Immunohistochemical staining of BrdU in the hippocampal field should normally be restricted to the SGZ of the dentate gyrus, as shown on the left.
  • the in vivo neurogenic screen employed was designed to detect small molecules that selectively stimulated BrdU incorporation into replicating cells of the SGZ. Infrequently, some compounds exhibited non-specific BrdU incorporation in ectopic regions, such as CA3, CAl, cortex, and striatum, as shown on the right. Any molecules that demonstrated ectopic incorporation of BrdU were eliminated from the study.
  • FIG. 4 Screening of 100 pools of 10 compounds identified 10 pools with pro- neurogenic efficacy.
  • FGF-2 fibroblast growth factor 2
  • aCSF artificial cerebrospinal fluid
  • Each pool of ten compounds was tested for pro-neurogenic efficacy over a 7 day period in two independent mice at 10 ⁇ M concentration for each individual compound.
  • Pools 7, 14, 18, 19, 41, 53, 54, 61, 69 and 70 displayed comparable stimulation of neural precursor cell proliferation as FGF-2 infusion. The majority of pools displayed no effect on hippocampal neural precursor cell proliferation.
  • FIG. 5 Re-evaluation of positive pools verified statistical significance of enhanced BrdU-incorporation. Subsequent to their initial identification, pools 7, 14, 18, 19, 41, 53, 54, 61, 69, and 70 were re-evaluated in 2 additional mice each. Results shown are average with SEM of all 4 mice evaluated for each compound. All pools significantly (*, P ⁇ 0.001, Student's t test) stimulated neural precursor cell proliferation in the hippocampal dentate gyrus SGZ relative to vehicle control.
  • FIG. 6 Pro-neurogenic pools were broken down to identify individual pro-neurogenic compounds, (a) In vivo evaluation of the ten individual compounds that composed pool #7 revealed that compound #3 stimulated either the proliferation or survival of neural precursor cells in the SGZ, whereas the remaining individual components of pool #7 did not. In this document this molecule is referred to as 'Example 45 Compound.' Each compound was infused at two different concentrations (100 ⁇ M (A and B) and 10 ⁇ M (C and D)) in two mice each.
  • Example 45 Compound showed either pro-neurogenic or neuroprotective activity at both concentrations.
  • FIG. 7 Neurogenic efficacy of orally administered Example 45 Compound was dose- related.
  • the graph on the left shows that the concentration of Example 45 Compound in brain tissue of mice that were administered compound by daily oral gavage for 7 consecutive days correlated with the dose of Example 45 Compound administered.
  • the graph on the right shows that pro-neurogenic or neuroprotective efficacy of Example 45 Compound was roughly double that of vehicle control at doses ranging from 5 to 40 mg/kg.
  • At decreasing dosage of Example 45 Compound the amount of neurogenesis decreased accordingly, until it reached levels no greater than vehicle control at compound doses below 1.0 mg/kg. Results shown are the average obtained from analysis of 5 adult wild type male mice at each dose.
  • FIG. 8 Analysis of molecules related structurally to Example 45 Compound revealed a region of the compound that could be chemically modified without loss of in vivo activity.
  • An in vivo SAR study was conducted using 37 chemical analogs of Example 45 Compound (labeled on the graph as P7C3A1-41), each evaluated in 4 or 5 adult C57/B6 male mice. Some analogs revealed activity comparable to the parent compound, whereas others showed significantly diminished activity, or evidence of pro-neurogenic effect intermediate between vehicle and FGF controls. This exercise enabled identification of regions of the parent compound that might be amenable to chemical modification without loss of activity.
  • Example 62 Compound retained robust activity with the aniline ring of Example 45 Compound substituted by an anisidine. This derivative compound was exploited to yield a fluorescent derivative by attaching a coumarin moiety to the N-phenyl ring.
  • Example 62 Activity of Example 62 Compound is enantiomer- specific, (a) (+) and (-) enantiomers of Example 62 Compound were prepared, (b) Evaluation of Example 62 Compound enantiomers showed that in vivo pro-neurogenic or neuroprotective efficacy was fully retained by the (+) enantiomer in a dose-dependent manner, while the (-) enantiomer showed diminished activity. Each enantiomer was evaluated at each dose in between 3 and 5 three month old adult wild type male C57/B6 mice.
  • Example 45 Compound enhances the survival of newborn neurons in the dentate gyrus
  • DCX doublecortin
  • an antigen specifically and transiently expressed in proliferating hippocampal neural precursor cells when they become irreversibly committed to neuronal differentiation was substantially increased in newborn neurons in mice that were administered
  • Example 45 Compound showed a statistically significant (*, P ⁇ 0.001, Student's t test) 25% increase in BrdU+ cells compared to the vehicle-only control group.
  • This difference between groups progressed with time such that mice that received a daily oral dose of Example 45 Compound for 30 days, starting 24 hours after the pulse administration of BrdU, exhibited a 5-fold increase in the abundance of BrdU+ cells in the dentate gyrus relative to vehicle-only controls.
  • BrdU+ cells were observed both in the SGZ and the granular layer of the dentate gyrus.
  • FIG 11 Quantification of short term (1 hour pulse) BrdU incorporation and cleaved- caspase 3 (CCSP3) formation in the dentate gyrus showed that NPAS3-deficient mice have the same rate of proliferation of newborn cells in the dentate as wild type littermates (BrdU), but roughly twice the level of programmed cell death (CCSP3) (*, P ⁇ 0.01, Student's t test). Three 6 week old male mice (NPAS3-deficient or wild type littermates) in each group were evaluated.
  • FIG. 12 Granule cell neurons in the dentate gyrus of NPAS 3 -deficient mice displayed morphological deficits in dendritic branching and spine density, (a) Golgi-Cox staining of the dentate gyrus illustrates that dendritic arborization of dentate gyrus granule cell neurons in npas3 ⁇ A mice is substantially less developed than in wild type littermates.
  • Results shown are representative of 15 sections from five 12-14 week old adult male mice of each genotype.
  • (b) In addition to obviously reduced dendritic length and branching, granular neurons in the dentate gyrus of npas3 v ⁇ mice also exhibited significantly reduced spine density relative to wild type littermates (*, P ⁇ 0.00001, Student's t test). These genotype-specific differences were not exhibited by neurons in the CAl region of the hippocampus.
  • FIG. 13 In hippocampal slice preparation from npas3 ⁇ / ⁇ mice, synaptic transmission was increased both in the outer molecular layer of the dentate gyrus (a) and the CAl region of the hippocampus (b) relative to hippocampal slices from wild type mice. Extended treatment with Example 45 Compound normalized synaptic responses in the dentate gyrus but not the CAl region of npas3 v ⁇ mice. Extended treatment with Example 45 Compound did not affect wild-type responses. Data are presented as the mean +SEM. Each group consisted of 1 or 2 slice preparation from each of 5 mice.
  • Figure 14 Example 45 Compound has pro-neurogenic or neuroprotective efficacy in the dentate gyrus of NPAS3-deficient animals.
  • Example 45 Compound Six 12 week old npas3 v ⁇ mice were orally administered vehicle or Example 45 Compound (20 mg/kg/d) for 12 days, and also injected daily with BrdU (50 mg/kg). At the end of day 12, mice were sacrificed and tissue was stained for BrdU and doublecortin (DCX). BrdU staining showed that Example 45 Compound increased the magnitude of neurogenesis in npas3 ⁇ A mice by roughly 4-fold, as graphically represented above (*, P ⁇ 0.001, Student's t test). DCX staining shows that Example 45 Compound also promoted more extensive process formation in differentiating neurons of the adult dentate gyrus in npas3 v ⁇ mice.
  • FIG. 15 Golgi-Cox staining of neurons in the dentate gyrus shows that extended daily treatment of npas3 v ⁇ mice with Example 45 Compound (20 mg/kg/d) enhanced dendritic arborization. Hi-power micrographs are shown on top, and a lower power micrograph illustrating the entire dentate gyrus is shown below.
  • Figure 16 Measured thickness of hippocampal subfields in npas3 ⁇ A and wild type littermate mice that were treated with Example 45 Compound (20 mg/kg/d) or vehicle every day from embryonic day 14 until 3 months of age demonstrated that Example 45 Compound selectively increased the thickness of the dentate gyrus granular cell layer to a level approaching wild type thickness (*, P ⁇ 0.01, Student's t test), without affecting thickness of the pyramidal cell layers of CAl or CA3 regions.
  • FIG. 17 Immunohistochemical detection of cleaved caspase 3 (CCSP3), a marker of apoptosis, showed elevated levels of programmed cell death in the dentate gyrus of NPAS 3 -deficient animals. Apoptosis in NPAS 3 -deficient animals was inhibited by treatment with Example 45 Compound (20 mg/kg/d, p. o., for 12 days), whereas analogous treatment with vehicle alone had no effect. Images shown are representative of 10-12 sections evaluated per animal, with 3-5 eight-week-old male NPAS 3 -deficient mice per group.
  • CCSP3 cleaved caspase 3
  • Figure 18 Cell viability assay after exposure of cultured primary cortical neurons to A ⁇ (25 - 35) for 48 hours shows that Example 45 Compound protected neurons from cell death compared to vehicle-treated (control) samples. Observed protection was afforded with the (+) enantiomer of Example 62 Compound, but less so with the (-) enantiomer. Data are presented as the mean +SEM.
  • FIG. 20 Fluorescently-labeled Example 62 Compound, termed FASDP, was exposed to cultured U2OS osteoblast cells and observed to localize with a distribution that overlapped with that of Mitotracker dye. This observation indicated that the site of action of Example 45 Compound is localized in mitochondria.
  • Example 45 Compound acts mechanistically in the mitochondria
  • Example 45 Compound as compared to a known drug, (a) Both Example 45 Compound and the Dimebon anti-histamine enhanced hippocampal neurogenesis (b), protected cultured cortical neurons from A ⁇ (25 - 35) -mediated cell death (c), and protected mitochondria from dissolution following toxic exposure to the calcium ionophore A23187 (d).
  • the Example 45 Compound exhibited a higher ceiling of efficacy than the Dimebon anti-histamine.
  • the Example 45 Compound performed with greater relative potency than the Dimebon antihistamine.
  • This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and/or promoting the survival of existing neurons by reducing neuronal cell death.
  • neurogenesis e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis
  • this invention features compounds having general formula (I):
  • R 1 , R 2 , R 3 , R 4 , R, R', L 1 , L 2 , A, and Z can be as defined anywhere herein.
  • variable e.g., R 1
  • R 1 a variable defined anywhere herein
  • the definitions for that particular variable include the first occurring and broadest generic definition as well as any sub-generic and specific definitions delineated anywhere in this specification.
  • one or two of R 1 , R 2 , R 3 , and R 4 is selected from halo, hydroxyl, sulfhydryl, Ci-C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, -NH 2 , -NH(C 1 -C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and nitro; and the others are hydrogen.
  • one or two of R 1 , R 2 , R 3 , and R 4 is selected from halo, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, and nitro; and the others are hydrogen.
  • one or two of R 1 , R 2 , R 3 , and R 4 (e.g., one of, e.g., R 3 ) is selected from halo, Ci-C 6 alkyl, and Ci-C 6 haloalkyl; and the others are hydrogen.
  • one or two of R 1 , R 2 , R 3 , and R 4 (e.g., one of, e.g., R 3 ) is selected from halo and C 1 -C 6 alkyl; and the others are hydrogen.
  • one or two of R 1 , R 2 , R 3 , and R 4 (e.g., one of, e.g., R 3 ) is halo (e.g., bromo or chloro) and Ci-C 6 alkyl; and the others are hydrogen.
  • one or two of R 1 , R 2 , R 3 , and R 4 (e.g., one of, e.g., R 3 ) is bromo; and the others are hydrogen.
  • R 3 is selected from halo, hydroxyl, sulfhydryl, Ci-C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, -NH 2 , -NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , -NHC(O)(C 1 -C 6 alkyl), and nitro; and each of R 1 , R 2 , and R 4 can be as defined anywhere herein.
  • R 3 is selected from halo, hydroxyl, sulfhydryl, Ci-C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, -NH 2 , -NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , -NHC(O)(C 1 -C 6 alkyl), and nitro; and each of R 1 , R 2 , and R 4 is hydrogen.
  • R 3 is selected from halo, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, Ci-C 6 alkyl, C 1 -C 6 haloalkyl, cyano, and nitro; and each of R 1 , R 2 , and R 4 can be as defined anywhere herein.
  • R 3 is selected from halo, Ci-C 6 alkoxy, Ci-C 6 haloalkoxy, Ci-C 6 alkyl, Ci-C 6 haloalkyl, cyano, and nitro; and each of R 1 , R 2 , and R 4 is hydrogen.
  • R is selected from halo, Ci-C 6 alkyl, and Ci-C 6 haloalkyl; and each of R 1 , R 2 , and R 4 can be as defined anywhere herein.
  • R 3 is selected from halo, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl; and each of R 1 , R 2 , and R 4 is hydrogen.
  • R 3 is selected from halo and Ci-C 6 alkyl; and each of R 1 ,
  • R 2 , and R 4 can be as defined anywhere herein.
  • R 3 is selected from halo and C 1 -C 6 alkyl; and each of R 1 , R 2 , and R 4 is hydrogen.
  • R 3 is halo (e.g., bromo or chloro); and each of R 1 , R 2 , and
  • R 4 can be as defined anywhere herein..
  • R 3 is halo (e.g., bromo or chloro); and each of R 1 , R 2 , and R 4 is hydrogen.
  • R 3 is bromo; and each of R 1 , R 2 , and R 4 can be as defined anywhere herein..
  • R 3 is bromo; and each of R 1 , R 2 , and R 4 is hydrogen.
  • each of R 1 , R 2 , R 3 , and R 4 is independently selected from hydrogen, halo, and Ci-C 6 alkyl.
  • each of R 1 , R 2 , R 3 , and R 4 is independently selected from hydrogen and halo(e.g., bromo or chloro).
  • each of R 1 , R 2 , R 3 , and R 4 is hydrogen. In some embodiments, when any one or more of R 1 , R 2 , R 3 , and R 4 can be a substituent other than hydrogen, said substituent, or each of said substituents, is other than Ci-C 6 alkyl (e.g., other than Q-C 3 alkyl, e.g., other than CH 3 ).
  • L 1 is Ci-C 3 (e.g., Ci-C 2 ) straight chain alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • L 1 is methylene (i.e., -CH 2 -). In other embodiments, L 1 is methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c . In embodiments, R c is Ci-C 6 alkyl (e.g., Ci-C 3 alkyl, e.g., CH 3 ).
  • L 1 is ethylene (i.e., -CH 2 CH 2 -). In other embodiments, L 1 is ethylene that is substituted with 1 or 2 (e.g., 1) independently selected R c . In embodiments, R c is Ci-C 6 alkyl (e.g., Ci-C 3 alkyl, e.g., CH 3 ).
  • L 2 is Q-C 3 (e.g., Ci-C 2 ) straight chain alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • L 2 is methylene (i.e., -CH 2 -).
  • L 1 is methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c .
  • R c is Q-C 6 alkyl (e.g., Q-C 3 alkyl, e.g., CH 3 ).
  • R c is Q- C 6 alkoxy, Ci-C 6 thioalkoxy, Ci-C 6 haloalkoxy, or Ci-C 6 thiohaloalkoxy.
  • R c can be Q-C 6 (e.g., Q-C 3 ) thioalkoxy, such as -SCH 3 .
  • L 2 is ethylene (i.e., -CH 2 CH 2 -). In other embodiments, L is ethylene that is substituted with 1 or 2 (e.g., 1) independently selected R c . For example, the ethylene carbon more proximal to Z in formula (I) can be substituted as described in the preceding paragraph.
  • L 2 is a bond that directly connects A in formula (I) to Z in formula (I).
  • each of L 1 and L 2 is, independently, C 1 -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • each of L 1 and L 2 is CH 2 .
  • one of L 1 and L 2 is CH 2 (e.g., L 1 ), and the other (e.g., L 2 ) is methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c , in which R c can be as defined anywhere herein.
  • each of L 1 and L 2 is methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c , in which R c can be as defined anywhere herein.
  • L 1 is C 1 -C 3 (e.g., Ci-C 2 ) straight chain alkylene, which is optionally substituted with from 1-2 independently selected R c
  • L 2 is a bond that directly connects A in formula (I) to Z in formula (I).
  • L 1 can be, for example, methylene (i.e., -CH 2 -) or methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c (e.g., Ci-C 6 alkyl, e.g., C 1 -C 3 alkyl, e.g., CH 3 ).
  • A is:
  • R A1 and R A2 are independently selected from hydrogen, halo, C 1 -C 3 alkyl, or OR 9 ; or
  • heterocycloalkylene containing from 3-5 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heterocycloalkylene is (a) substituted with 1 oxo; and (b) is optionally further substituted with from 1-4 independently selected R a .
  • A is CR A1 R A2 , in which each of R A1 and R ⁇ is, independently, hydrogen, halo, Ci-C 3 alkyl, or OR 9 (e.g., hydrogen, halo, or OR 9 ).
  • A can be CR A1 R A2 , in which each of R A1 and R A2 is, independently, hydrogen, halo, or C 1 -C 3 alkyl.
  • A can be CR A1 R A2 , in which one of R A1 and R ⁇ is halo (e.g., fluoro), and the other of R A1 and R A2 is, independently, hydrogen, halo, or C 1 -C 3 alkyl (e.g., hydrogen).
  • one of R A1 and R ⁇ is hydrogen. In embodiments, one of R A1 and R ⁇ is halo or OR 9 , and the other is hydrogen.
  • one of R A1 and R ⁇ can be OR 9 .
  • the other of R A1 and R A2 can be as defined anywhere herein; e.g., the other of R A1 and R ⁇ can be hydrogen or C 1 -C 3 alkyl.
  • one of R A1 and R ⁇ can be OR 9 , and the other of R A1 and R A2 is hydrogen.
  • R 9 can be hydrogen or R 9 can be C 1 - C 3 alkyl (e.g., CH 3 ).
  • one of R A1 and R ⁇ can be halo.
  • the other of R A1 and R A2 can be as defined anywhere herein; e.g., the other of R A1 and R ⁇ can be hydrogen, Ci-C 3 alkyl, or halo.
  • one of R A1 and R ⁇ can be halo (e.g., fluoro), and the other of R A1 and R A2 is hydrogen.
  • one of R A1 and R A2 is halo or OR 9 , and the other is hydrogen.
  • one of R A1 and R A2 can be OR 9 , and the other is hydrogen.
  • R can be hydrogen.
  • R can be C 1 -C 3 alkyl (e.g., CH 3 ).
  • one of R A1 and R ⁇ can be halo (e.g., fluoro), and the other is hydrogen.
  • each of R A1 and R ⁇ is a substituent other than hydrogen.
  • each of R A1 and R A2 can be halo (e.g., fluoro).
  • one of R A1 and R ⁇ can be OR 9 (e.g., in which R 9 is hydrogen), and the other is Ci-C 3 alkyl (e.g., CH 3 ).
  • each of R A1 and R ⁇ can be C 1 -C 3 alkyl (e.g., CH 3 ).
  • each of R A1 and R ⁇ is hydrogen.
  • Embodiments can further include any one or more of the following features.
  • the carbon attached to R A1 and R A2 when substituted with four different substituents, the carbon attached to R A1 and R ⁇ can have the R configuration.
  • the carbon attached to R A1 and R A2 can have the S configuration.
  • A is heterocycloalkylene containing from 3-5 ring atoms, in which from 1-2 of the ring atoms is independently selected from N, NH, N(C 1 - C 3 alkyl), O, and S; and wherein said heterocycloalkylene is (a) substituted with 1 oxo (e.g., 1 oxo on a ring carbon); and (b) is optionally further substituted with from 1-4 independently selected R a .
  • 1 oxo e.g., 1 oxo on a ring carbon
  • A is heterocycloalkylene containing 5 ring atoms, in which from 1-2 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heterocycloalkylene is (a) substituted with 1 oxo; and (b) is optionally further substituted with from 1-4 independently selected R a .
  • A can be:
  • A is CR ⁇ R* 2 , wherein each of R A1 and R A2 is independently selected from hydrogen, halo, C 1 -C 3 alkyl, or OR 9 ; and each of L 1 and L 2 is, independently, C 1 -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • R A1 and R ⁇ can be as defined anywhere herein.
  • Each of L 1 and L 2 is CH 2 .
  • L 1 and L 2 are CH 2 (e.g., L 1 ), and the other (e.g., L 2 ) is methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c , in which R c can be as defined anywhere herein.
  • R c can be as defined anywhere herein.
  • L 1 can be CH 2 ;
  • R A1 and R ⁇ are hydrogen
  • L 2 can be methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c (e.g., C 1 -C 6 (e.g., C 1 -C 3 ) alkyl, such as CH 3 ; or C 1 -C 6 (e.g., C 1 - C 3 ) thioalkoxy, such as -SCH 3 );
  • R c e.g., C 1 -C 6 (e.g., C 1 -C 3 ) alkyl, such as CH 3 ; or C 1 -C 6 (e.g., C 1 - C 3 ) thioalkoxy, such as -SCH 3 );
  • Each of L 1 and L 2 is methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c , in which R c can be as defined anywhere herein.
  • R c can be as defined anywhere herein.
  • each of R A1 and R A2 can be a substituent other than hydrogen (e.g., one of which is CH 3 ), and
  • each of L 1 and L 2 is methylene that is substituted with Ci-C 3 alkyl, such as CH 3 ).
  • A is heterocycloalkylene containing from 3-5 (e.g., 5) ring atoms, in which from 1-2 of the ring atoms is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heterocycloalkylene is (a) substituted with 1 oxo; and (b) is optionally further substituted with from 1-4 independently selected R a ; and L 1 is C 1 -C 3 (e.g., C 1 -C 2 ) straight chain alkylene, which is optionally substituted with from 1-2 independently selected R c , and
  • L 2 is a bond that directly connects A in formula (I) to Z in formula (I).
  • Z is:
  • heterocycloalkenyl containing from 5-6 ring atoms, wherein from 1-3 of the ring atoms is independently selected from N, NH, N(Ci-C 6 alkyl), NHC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocycloalkenyl is optionally substituted with from 1-4 independently selected R a ;
  • heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 independently selected R b .
  • Z is as defined in (i), (iii), (iv), (v), (vi), or (vii) in the preceding paragraph.
  • Z is as defined in (i), (iii), (iv), (v), or (vii) in the preceding paragraph.
  • Z is as defined in (i), (iii), (v), or (vii) in the preceding paragraph.
  • Z is as defined in (i), (iii), or (iv) in the preceding paragraph.
  • Z is: (i) -NR 10 R 11 ; or (iii) -OR 12 ; or
  • heterocycloalkenyl containing from 5-6 ring atoms, wherein from 1-3 of the ring atoms is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocycloalkenyl is optionally substituted with from 1-4 independently selected R a .
  • Z is: (i) -NR 10 R 11 ; or (iii) -OR 12 .
  • Z is: (i) -NR 10 R 11 ; or (iv) -S(O) n R 13 , wherein n is 0, 1, or 2.
  • Z is: (iii) -OR 12 ; or (iv) -S(O) n R 13 , wherein n is 0, 1, or 2.
  • Z does not include heterocyclyl (e.g., a nitrogenous heterocyclyl, e.g., piperazinyl or piperidinyl) as part of its structure (e.g., as a fused ring or attached to another ring by a bond).
  • heterocyclyl e.g., a nitrogenous heterocyclyl, e.g., piperazinyl or piperidinyl
  • Z does not include heterocyclyl (e.g., a nitrogenous heterocyclyl, e.g., piperazinyl or piperidinyl) as part of its structure (e.g., as a fused ring or attached to another ring by a bond).
  • Z is other than heterocycloalkenyl containing from 5-6 ring atoms, wherein from 1-3 of the ring atoms is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocycloalkenyl is optionally substituted with from 1-4 independently selected R a .
  • Z is other than heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 - C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 independently selected R b (e.g., other than pyridyl).
  • Z is -NR 10 R 11 .
  • one of R 10 and R 11 is hydrogen, and the other of R 10 and R 11 is a substituent other than hydrogen.
  • one of R 10 and R 11 is hydrogen or a substituent other than hydrogen, and the other of R 10 and R 11 is a substituent other than hydrogen.
  • each of R 10 and R 11 is a substituent other than hydrogen.
  • each of R 10 and R 11 is hydrogen.
  • one of R 10 and R 11 is independently selected from the substituents delineated collectively in (b), (c), (g) through (k), and (1) below:
  • heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b ;
  • the aryl portion is optionally substituted with from 1-4 independently selected R b , and
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;
  • the aryl portion from is optionally substituted with from 1-4 independently selected R b , and
  • heterocyclyl portion is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ;
  • (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • heterocyclyl portion is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocyclyl portion is optionally substituted with from 1-3 independently selected R a ;
  • (1) from 1-2 of the ring atoms of the heteroaryl portion is independently selected from N, NH, N(C 1 -C 3 alkyl), O, and S; and wherein said heteroaryl portion is optionally substituted with from 1-3 independently selected R b ; and
  • the cycloalkyl portion is optionally substituted with from 1-4 independently selected R a ;
  • C 7 -C 12 aralkyl wherein the aryl portion is optionally the aryl portion from is optionally substituted with from 1-4 independently selected R b , and the other of R 10 and R 11 can be as defined anywhere herein.
  • R 10 and R 11 cannot be C 3 -Cg cycloalkyl or C 3 -Cg cycloalkenyl, each of which is optionally substituted with from 1-4 independently selected R a .
  • one of R 10 and R 11 is independently selected from the substituents delineated collectively in (b), (c), (g) through (j), and (1) above; and the other of R 10 and R 11 can be as defined anywhere herein.
  • one of R 10 and R 11 is independently selected from the substituents delineated collectively in (b), (c), and (g) through (j); and the other of R 10 and R » 11 can be as defined anywhere herein.
  • one of R 10 and R 11 is independently selected from:
  • one of R 10 and R 11 is C 6 -CiO aryl (e.g., C 6 ) that is optionally substituted with from 1-4 (e.g., 1-3, 1-2, or 1) R b ; and the other of R 10 and R 11 can be as defined anywhere herein.
  • R b at each occurrence is independently selected from halo; or Ci-C 6 alkoxy; Ci-C 6 haloalkoxy; Ci-C 6 thioalkoxy; Ci-C 6 thiohaloalkoxy; Ci-C 6 alkyl, Ci-C 6 haloalkyl, -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , and -NHC(O)(Ci-C 6 alkyl), each of which is optionally substituted with from 1-3 independently selected R e .
  • R b at each occurrence is independently selected from Q- C 6 alkoxy; Ci-C 6 haloalkoxy; Ci-C 6 thioalkoxy; and Ci-C 6 thiohaloalkoxy, each of which is optionally substituted with from 1-3 independently selected R e .
  • R b can further include halo.
  • R b at each occurrence is independently selected from Q- C 6 alkoxy and Ci-C 6 haloalkoxy, each of which is optionally substituted with from 1-3 independently selected R e .
  • R b can further include halo.
  • R b at each occurrence is independently selected from Q- C 6 alkoxy, each of which is optionally substituted with from 1-3 independently selected R e .
  • R b is Ci-C 6 alkoxy (e.g., OCH 3 ).
  • R b can further include halo.
  • one of R 10 and R 11 is unsubstituted phenyl, and the other of R 10 and R 11 can be as defined anywhere herein.
  • one of R 10 and R 11 is phenyl that is substituted with 1 R b , and the other of R 10 and R 11 can be as defined anywhere herein.
  • R b can be as defined anywhere herein (e.g., R b can be Q-C 6 alkoxy, e.g., OCH 3 ).
  • one of R 10 and R 11 can be 3-methoxyphenyl.
  • R b can bfurther include halo.
  • R 10 and R 11 when one of R 10 and R 11 is independently selected from the substituents delineated collectively in (b), (c), (g) through (k), and (1) above, the other of R 10 and R 11 can be:
  • Ci-C 6 alkyl or Ci-C 6 haloalkyl e.g., Ci-C 6 alkyl, each of which is optionally substituted with from 1-3 R d ; or (e) -C(O)(Ci-C 6 alkyl), -C(O)(Ci-C 6 haloalkyl), or -C(O)O(Ci-C 6 alkyl); or
  • R 10 and R 11 is: (a) hydrogen; or
  • Ci-C 6 alkyl or Ci-C 6 haloalkyl e.g., Ci-C 6 alkyl, each of which is optionally substituted with from 1-3 R d ; or
  • R 10 and R 11 is: (a) hydrogen; or
  • Ci-C 6 alkyl or Q-C 6 haloalkyl e.g., Q-C 6 alkyl, each of which is optionally substituted with from 1-3 R d ; or
  • R 10 and R 11 can be: (a) hydrogen; or
  • Ci-C 6 alkyl e.g., C1-C 3 alkyl, e.g., CH 3 ), which is optionally substituted with from 1-3 R d ; or
  • R 10 and R 11 can be: (a) hydrogen; or
  • Ci-C 6 alkyl e.g., Q-C 3 alkyl, e.g., CH 3
  • Ci-C 6 alkyl which is optionally substituted with from 1-3 R d .
  • the other of R 10 and R 11 can be hydrogen.
  • R 10 and R 11 can be (d) or (e) or any subset thereof.
  • one of R 10 and R 11 is C 6 -CiO (e.g., C 6 ) aryl that is optionally substituted with from 1-4 R b , and the other is hydrogen or Ci-C 6 alkyl (e.g.,
  • Ci-C 3 alkyl e.g., CH 3 ).
  • one of R 10 and R 11 is C 6 -Ci O (e.g., C 6 ) aryl that is optionally substituted with from 1-4 R D , and the other is hydrogen.
  • one of R 10 and R 11 is unsubstituted phenyl, and the other is hydrogen.
  • one of R 10 and R 11 is phenyl that is substituted with 1 R b , and the other is hydrogen.
  • R b is Ci-C 6 alkoxy (e.g., Ci-C 3 alkoxy, e.g., OCH 3 ).
  • one of R 10 and R 11 is 3-methoxyphenyl, and the other is hydrogen.
  • each of R 10 and R 11 cannot be optionally substituted naphthyl (e.g., each of R 10 and R 11 cannot be unsubstituted naphthyl).
  • each of R 10 and R 11 is other than optionally substituted naphthyl (e.g., unsubstituted naphthyl) when R and R' are defined according to definitions (1), (2), and (4); and A is CR A1 R ⁇ (e.g., CHOR 9 , e.g., CHOH), and each of L 1 and L 2 is C 1 -C 3 alkylene (e.g., each of L 1 and L 2 is CH 2 ).
  • one of R 10 and R 11 is hydrogen, and the other is heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b .
  • one of R 10 and R 11 is hydrogen, and the other is heteroaryl containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-2 R b .
  • Z is -OR 12 .
  • R 12 is Ci-C 6 alkyl or Ci-C 6 haloalkyl, each of which is optionally substituted with from 1-3 R c . In some embodiments, R 12 is Ci-C 6 alkyl, which is optionally substituted with from 1-3 R c .
  • R 12 is C 1 -C 6 alkyl (e.g., C 1 -C 3 alkyl, e.g., CH 3 ).
  • R 12 is C 1 -C 6 alkyl (e.g., Ci-C 3 alkyl, e.g., CH 3 ), which is optionally substituted with from 1-3 (e.g., 1 or 2, e.g., 1) R c .
  • each occurrence of R c can be independently selected from -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , and -NHC(O)(C 1 -C 6 alkyl).
  • R 12 is C 6 -Ci O aryl that is optionally substituted with from 1- 4 (e.g., 1-3, 1-2, or 1) R b .
  • R b at each occurrence is independently selected from halo; or C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, Ci-C 6 haloalkyl, -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , and -NHC(O)(Ci-C 6 alkyl), each of which is optionally substituted with from 1-3 independently selected R e .
  • R b at each occurrence is independently selected from C 1 - C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; and C 1 -C 6 thiohaloalkoxy, each of which is optionally substituted with from 1-3 independently selected R e .
  • R b at each occurrence is independently selected from C 1 - C 6 alkoxy and C 1 -C 6 haloalkoxy, each of which is optionally substituted with from 1-3 independently selected R e .
  • R b at each occurrence is independently selected from C 1 - C 6 alkoxy, each of which is optionally substituted with from 1-3 independently selected R e .
  • R b is C 1 -C 6 alkoxy (e.g., OCH 3 ).
  • R b can further include halo.
  • R 12 is unsubstituted phenyl.
  • R 12 is phenyl that is substituted with 1 R b .
  • R b can be as defined anywhere herein (e.g., R b can be C 1 -C 6 alkoxy, e.g., OCH 3 ).
  • R 12 can be 3-methoxyphenyl.
  • Z is -S(O) n R 13 , in which n can be 0, 1, or 2.
  • R 13 is C 6 -Ci O aryl that is optionally substituted with from 1- 4 (e.g., 1-3, 1-2, or 1) R b .
  • R b at each occurrence is independently selected from halo; or C 1 -C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; C 1 -C 6 thiohaloalkoxy; C 1 -C 6 alkyl, Ci-C 6 haloalkyl, -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , and -NHC(O)(Ci-C 6 alkyl), each of which is optionally substituted with from 1-3 independently selected R e .
  • R b at each occurrence is independently selected from C 1 - C 6 alkoxy; C 1 -C 6 haloalkoxy; C 1 -C 6 thioalkoxy; and C 1 -C 6 thiohaloalkoxy, each of which is optionally substituted with from 1-3 independently selected R e .
  • R b at each occurrence is independently selected from C 1 - C 6 alkoxy and C 1 -C 6 haloalkoxy, each of which is optionally substituted with from 1-3 independently selected R e .
  • R b at each occurrence is independently selected from C 1 - C 6 alkoxy, each of which is optionally substituted with from 1-3 independently selected R e .
  • R b is C 1 -C 6 alkoxy (e.g., OCH 3 ).
  • R b can further include halo.
  • R 13 is unsubstituted phenyl.
  • R 13 is phenyl that is substituted with 1 R b .
  • R b can be as defined anywhere herein (e.g., R b can be C 1 -C 6 alkoxy, e.g., OCH 3 ).
  • R 13 can be 3-methoxyphenyl.
  • R 12 and/or R 13 cannot be substituted phenyl. In embodiments, R 12 and/or R 13 cannot be substituted phenyl when R and R' are defined according to definition (1); and A is CR A1 R ⁇ (e.g., CHOR 9 , e.g., CHOH), and each of L 1 and L 2 is C 1 - C 3 alkylene (e.g., each of L 1 and L 2 is CH 2 ).
  • Z is heterocycloalkenyl containing from 5-6 ring atoms, wherein from 1-3 of the ring atoms is independently selected from N, NH, N(C 1 - C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocycloalkenyl is optionally substituted with from 1-4 independently selected R a .
  • Z is heterocycloalkenyl containing 6 ring atoms, wherein from 1-3 of the ring atoms is independently selected from N, NH, N(Ci-C 6 alkyl), NC(O)(Ci-C 6 alkyl), O, and S; and wherein said heterocycloalkenyl is optionally substituted with from 1-4 independently selected R a .
  • from 1-3 of the ring atoms is independently selected from N, NH, N(Ci-C 6 alkyl), and NC(O)(Ci-C 6 alkyl).
  • Z can be:
  • Z is heteroaryl containing from 5-14 ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 R b .
  • Z is heteroaryl containing from 5-10 ring atoms, wherein from 1-4 of the ring atoms is independently selected from N, NH, and N(Ci-C 3 alkyl); and wherein said heteroaryl is optionally substituted with from 1-2 R b .
  • each of R 5 , R 6 , R 7 , and R 8 is independently selected from hydrogen, halo, hydroxyl, sulfhydryl, Ci-C 6 alkoxy, Ci-C 6 thioalkoxy, Ci-C 6 haloalkoxy, Ci-C 6 halothioalkoxy, Ci-C 6 alkyl, Ci-C 6 haloalkyl, cyano, -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(C r C 6 alkyl), and nitro.
  • R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , A, and Z can be as defined anywhere herein.
  • one or two of R 5 , R 6 , R 7 , and R 8 is selected from halo, hydroxyl, sulfhydryl, Q-C 6 alkoxy, Q-C 6 thioalkoxy, Q-C 6 haloalkoxy, Ci-C 6 thiohaloalkoxy, Ci-C 6 alkyl, Ci-C 6 haloalkyl, cyano, -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and nitro; and the others are hydrogen.
  • one or two of R 5 , R 6 , R 7 , and R 8 (e.g., one of, e.g., R 6 ) is selected from halo, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, and nitro; and the others are hydrogen.
  • one or two of R 5 , R 6 , R 7 , and R 8 (e.g., one of, e.g., R 6 ) is selected from halo, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl; and the others are hydrogen.
  • IInn cceerrttaaiinn eemmbbooddiimmeennttss,, oonnee oorr ttwwoo ooff RR 55 ,, RR 66 ,, RR 77 ,, aanndd RR 88 (e.g., one of, e.g., R 6 ) is selected from halo and Ci-C 6 alkyl; and the others are hydrogen.
  • IInn cceerrttaaiinn eemmbbooddiimmeennttss,, oonnee oorr ttwwoo ooff RR 55 ,, RR 66 ,, RR 77 ,, aanndd RR 88 e.g., one of, e.g., R 6
  • halo e.g., bromo or chloro
  • R 6 is selected from halo, hydroxyl, sulfhydryl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and nitro; and each of R 5 , R 7 , and R 8 can be as defined anywhere herein.
  • R 6 is selected from halo, hydroxyl, sulfhydryl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, -NH 2 , -NH(Ci-C 6 alkyl), N(Ci-C 6 alkyl) 2 , -NHC(O)(Ci-C 6 alkyl), and nitro; and each of R 5 , R 7 , and R 8 is hydrogen.
  • R 6 is selected from halo, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, Ci-C 6 alkyl, Ci-C 6 haloalkyl, cyano, and nitro; and each of R 1 , R 2 , and R 4 can be as defined anywhere herein.
  • R 6 is selected from halo, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, and nitro; and each of R 5 , R 7 , and R 8 is hydrogen.
  • R 6 is selected from halo, Ci-C 6 alkyl, and Ci-C 6 haloalkyl; and each of R 5 , R 7 , and R 8 can be as defined anywhere herein.
  • R 6 is selected from halo and Ci-C 6 alkyl; and each of R 5 , R 7 , and R 8 can be as defined anywhere herein.
  • R 6 is selected from halo and C 1 -C 6 alkyl; and each of R 5 ,
  • R 7 , and R 8 is hydrogen.
  • R 6 is halo (e.g., bromo or chloro); and each of R 5 , R 7 , and R 8 can be as defined anywhere herein..
  • R 6 is halo (e.g., bromo or chloro); and each of R 5 , R 7 , and R 8 is hydrogen.
  • R 6 is bromo; and each of R 5 , R 7 , and R 8 can be as defined anywhere herein..
  • R 6 is bromo; and each of R 5 , R 7 , and R 8 is hydrogen.
  • each of R 5 , R 6 , R 7 , and R 8 is independently selected from hydrogen, halo, and Ci-C 6 alkyl.
  • IInn cceerrttaaiinn eemmbbooddiimmeennttss, i each of R 5 , R 6 , R 7 , and R 8 is independently selected from hydrogen and halo(e.g., bromo or chloro).
  • each of R 5 , R 6 , R 7 , and R 8 is hydrogen.
  • R 5 , R 6 , R 7 , and R 8 can be a substituent other than hydrogen
  • said substituent, or each of said substituents is other than Ci-C 6 alkyl (e.g., Ci-C 3 alkyl, e.g., CH 3 ).
  • Embodiments can include any one or more of the features described anywhere herein, including (but not limited to) those described below.
  • R 1 , R 2 , R 3 , and R 4 can be as defined anywhere herein.
  • R is selected from halo, hydroxyl, sulfhydryl, Ci-C 6 alkoxy, Ci-C 6 thioalkoxy, Ci-C 6 haloalkoxy, C 1 -C 6 thiohaloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cyano, -NH 2 , - NH(Ci-C 6 alkyl), N(C 1 -C 6 alkyl) 2 , -NHC(O)(C 1 -C 6 alkyl), and nitro; and each of R 1 , R 2 , and R 4 can be as defined anywhere herein (e.g., each of R 1 , R 2 , and R 4 is hydrogen).
  • R 3 is selected from halo and Ci-C 6 alkyl; and each of R 1 , R 2 , and R 4 can be as defined anywhere herein (e.g., each of R 1 , R 2 , and R 4 is hydrogen).
  • R 3 is halo (e.g., bromo or chloro); and each of R 1 , R 2 , and R 4 can be as defined anywhere herein (e.g., each of R 1 , R 2 , and R 4 is hydrogen).
  • R 3 is bromo; and each of R 1 , R 2 , and R 4 can be as defined anywhere herein (e.g., each of R 1 , R 2 , and R 4 is hydrogen).
  • R 1 , R 2 , R 3 , and R 4 is independently selected from hydrogen and halo(e.g., bromo or chloro).
  • R 1 , R 2 , R 3 , and R 4 is hydrogen.
  • Each of L 1 and L 2 is, independently, Ci -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • Each of L 1 and L 2 is CH 2 .
  • L 1 and L 2 are CH 2 (e.g., L 1 ), and the other (e.g., L 2 ) is methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c , in which R c can be as defined anywhere herein.
  • Each of L 1 and L 2 is methylene that is substituted with 1 or 2 (e.g., 1) independently selected R c , in which R c can be as defined anywhere herein.
  • L 1 is C 1 -C 3 (e.g., Ci-C 2 ) straight chain alkylene, which is optionally substituted with from 1-2 independently selected R c , and L 2 is a bond that directly connects A in formula (I) to Z in formula (I).
  • ⁇ C ⁇ C 1 -C 3 (e.g., Ci-C 2 ) straight chain alkylene, which is optionally substituted with from 1-2 independently selected R c
  • L 2 is a bond that directly connects A in formula (I) to Z in formula (I).
  • R A1 and R ⁇ is OR 9 , and the other is hydrogen.
  • R 9 can be hydrogen.
  • R 9 can be C 1 -C 3 alkyl (e.g., CH 3 ).
  • R A1 and R ⁇ can be halo (e.g., fluoro), and the other is hydrogen.
  • Each of R A1 and R ⁇ can be a substituent other than hydrogen.
  • each of R A1 and R A2 can be halo (e.g., fluoro).
  • one of R A1 and R A2 can be OR 9 (e.g., in which R 9 is hydrogen), and the other is Ci-C 3 alkyl (e.g., CH 3 ).
  • R A1 and R ⁇ are hydrogen.
  • R A is CR ⁇ R* 2 , wherein each of R A1 and R A2 is independently selected from hydrogen, halo, Ci-C 3 alkyl, or OR 9 ; and each of L 1 and L 2 is, independently, Ci-C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • Z is -NR 10 R 11 , in which R 10 and R 11 can be as defined anywhere herein.
  • R 10 and R 11 is C 6 -Ci O aryl that is optionally substituted with from 1-4 R b .
  • the other of R 10 and R 11 is hydrogen or C 1 -C 3 alkyl (e.g., CH 3 ).
  • the other of R 10 and R 11 is hydrogen.
  • one of R 10 and R 11 is unsubstituted phenyl, and the other is hydrogen.
  • one of R 10 and R 11 is phenyl that is substituted with 1 R b , and the other is hydrogen.
  • R b is Ci-C 6 alkoxy (e.g., Ci-C 3 alkoxy, e.g., OCH 3 ).
  • one of R 10 and R 11 is 3-methoxyphenyl, and the other is hydrogen.
  • Z is -OR 12 or -S(O) n R 13 , in which R 12 and R 13 can be as defined anywhere herein.
  • Embodiments can include features from any one, two, three, or four of ⁇ A ⁇ , ⁇ B ⁇ , ⁇ C ⁇ , and ⁇ D ⁇ ; or any combinations thereof.
  • R is a substituent other than hydrogen (e.g., halo and Ci-C 6 alkyl; e.g., halo, e.g., bromo); and and each of R 1 , R 2 , and R 4 can be as defined anywhere herein (e.g., each of R 1 , R 2 , and R 4 is hydrogen); and R 6 is a substituent other than hydrogen (e.g., halo and Ci-C 6 alkyl; e.g., halo, e.g., bromo); and and each of R 5 , R 7 , and R 8 can be as defined anywhere herein (e.g., each of R 5 , R 7 , and R 8 is hydrogen).
  • R is a substituent other than hydrogen (e.g., halo and Ci-C 6 alkyl; e.g., halo, e.g., bromo); and and each of R 1 , R 2 , and R 4 can be as defined anywhere herein (e.g., each of R 1 , R 2 , and R 4 is hydrogen); and
  • R 6 is a substituent other than hydrogen (e.g., halo and Ci-C 6 alkyl; e.g., halo, e.g., bromo); and and each of R 5 , R 7 , and R 8 can be as defined anywhere herein (e.g., each of R 5 , R 7 , and R 8 is hydrogen); and
  • A is CR ⁇ R* 2 , wherein each of R A1 and R A2 is independently selected from hydrogen, halo, C 1 -C 3 alkyl, or OR 9 ; and each of L 1 and L 2 is, independently, C 1 -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c .
  • Embodiments can include any one or more features described herein (e.g., as described under ⁇ B ⁇ and ⁇ C ⁇ above).
  • R 3 is a substituent other than hydrogen (e.g., halo and C 1 -C 6 alkyl; e.g., halo, e.g., bromo); and and each of R 1 , R 2 , and R 4 can be as defined anywhere herein (e.g., each of R 1 , R 2 , and R 4 is hydrogen); and
  • R 6 is a substituent other than hydrogen (e.g., halo and Ci-C 6 alkyl; e.g., halo, e.g., bromo); and and each of R 5 , R 7 , and R 8 can be as defined anywhere herein (e.g., each of R 5 , R 7 , and R 8 is hydrogen); and
  • A is CR ⁇ R* 2 , wherein each of R A1 and R A2 is independently selected from hydrogen, halo, C 1 -C 3 alkyl, or OR 9 ; and each of L 1 and L 2 is, independently, C 1 -C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c ; and
  • Z is -NR 10 R 11 , in which R 10 and R 11 can be as defined anywhere herein.
  • Embodiments can include any one or more features described herein (e.g., as described under ⁇ B ⁇ , ⁇ C ⁇ , and ⁇ D ⁇ above).
  • each of L 1 and L 2 is CH 2 .;
  • R A is CR ⁇ R ⁇ , wherein one of R A1 and R A2 is OR 9 , and the other is hydrogen.
  • Z is -NR 10 R 11 ; and each of R 10 and R 11 is independently selected from
  • Embodiments can include any one or more features described herein (e.g., as described under ⁇ A ⁇ , ⁇ C ⁇ , and ⁇ D ⁇ above).
  • R A is CR ⁇ R* 2 , in which each of R A1 and R ⁇ is, independently, hydrogen, halo, or Ci-C 3 alkyl; or
  • R A is CR ⁇ R ⁇ , in which one of R A1 and R ⁇ is halo (e.g., fluoro), and the other of R A1 and R ⁇ is, independently, hydrogen, halo, or Ci-C 3 alkyl (e.g., hydrogen); or
  • R A is CR A1 R A2 , in which one of R A1 and R ⁇ is halo (e.g., fluoro), and the other of R A1 and R ⁇ is hydrogen; and
  • R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , and Z can be as defined anywhere herein; or a salt (e.g., pharmaceutically acceptable salt) thereof.
  • Embodiments can include features from any one, two, three, or four of ⁇ A ⁇ , ⁇ B ⁇ , ⁇ C ⁇ , and ⁇ D ⁇ ; or any combinations thereof.
  • one of R A1 and R ⁇ can be OR 9 .
  • the other of R A1 and R A2 can be as defined anywhere herein; e.g., the other of R A1 and R ⁇ can be hydrogen or C 1 -C 3 alkyl.
  • one of R A1 and R ⁇ can be OR 9 , and the other of R A1 and R ⁇ is hydrogen.
  • R 9 can be hydrogen; and R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , and Z can be as defined anywhere herein; or a salt (e.g., pharmaceutically acceptable salt) thereof.
  • one or more of the following apply, e.g., when A is CHOH and
  • each of R 3 and R 6 is CH 3 ; and/or each of R 3 and R 6 is bromo; and/or each of R 3 and R 6 is chloro; and/or one of R 3 and R 6 is CH 3 (e.g., R 6 ), and the other is bromo (e.g., R 3 );
  • R 10 and R 11 are heteroaryl as defined anywhere herein;
  • L 1 and/or L 2 is C 2 -C 3 alkylene (optionally substituted);
  • Embodiments can include features from any one, two, three, or four of ⁇ A ⁇ , ⁇ B ⁇ , ⁇ C ⁇ , and ⁇ D ⁇ ; or any combinations thereof.
  • Z is other than NR 10 R 11 ; and R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , Z, and A can be as defined anywhere herein; or a salt (e.g., pharmaceutically acceptable salt) thereof.
  • (B) and/or (C) applies.
  • Embodiments can include features from any one, two, three, or four of ⁇ A ⁇ , ⁇ B ⁇ , ⁇ C ⁇ , and ⁇ D ⁇ ; or any combinations thereof.
  • Z is -OR 12 and/or -S(O) n R 13 ; and R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , and A can be as defined anywhere herein; or a salt (e.g., pharmaceutically acceptable salt) thereof.
  • (B) and/or (C) applies.
  • Embodiments can include features from any one, two, three, or four of ⁇ A ⁇ , ⁇ B ⁇ , ⁇ C ⁇ , and ⁇ D ⁇ ; or any combinations thereof.
  • Embodiments can include features from any one, two, three, or four of ⁇ A ⁇ , ⁇ B ⁇ , ⁇ C ⁇ , and ⁇ D ⁇ ; or any combinations thereof.
  • each of R and R' is, independently, hydrogen, C 1 - C 6 alkyl, or Ci-C 6 haloalkyl.
  • R and R' can each be the same or different.
  • each of R and R' is, independently, C 1 -C 6 alkyl, e.g., each of R and R' is CH 3 .
  • each of R and R' is hydrogen.
  • Embodiments can include any one or more of the features described anywhere herein, including (but not limited to) those described in conjunction with Formula (III).
  • R a for purposes of clarification and illustration, a non-limiting example of these compounds is provided below (formula (IV)):
  • R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , A, and Z can be as defined anywhere herein.
  • Embodiments can include any one or more of the features described anywhere herein, including (but not limited to) those described in conjunction with Formula (III).
  • R , 63 can be hydrogen or C 1 -C 3 alkyl (e.g., CH 3 ).
  • each of L 1 and L 2 must be Ci-C 3 alkylene, which is optionally substituted with from 1-2 independently selected R c when A is CH 2 ; or
  • Z must be other than heteroaryl containing from 5-14 (e.g., 5-6 or 6)ring atoms, wherein from 1-6 of the ring atoms is independently selected from N, NH, N(C 1 - C 3 alkyl), O, and S; and wherein said heteroaryl is optionally substituted with from 1-4 independently selected R b ; e.g., other than substituted pyridyl, e.g., other than pyridyl substituted with C 1 -C 3 alkyl (e.g., CH 3 ), e.g., other than 2 or 6-methylpyridyl.
  • R a for purposes of clarification and illustration, a non-limitinj example of such compounds is provided below (formula (V)):
  • R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , A, and Z can be as defined anywhere herein.
  • Embodiments can include any one or more of the features described anywhere herein, including (but not limited to) those described in conjunction with Formula (III).
  • R b a fused heteroaryl ring containing from 5-6 ring atoms, wherein from 1-2 of the ring atoms is independently selected from N, NH, N(Ci-C 3 alkyl), O, and S; and wherein said heteroaryl ring is optionally substituted with from 1-3 independently selected R b .
  • Embodiments can include any one or more of the features described anywhere herein, including (but not limited to) those described in conjunction with Formula (III).
  • the compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, enantiomerically enriched mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.
  • the compounds of this invention may also contain linkages (e.g., carbon-carbon bonds, carbon-nitrogen bonds such as amide bonds) wherein bond rotation is restricted about that particular linkage, e.g. restriction resulting from the presence of a ring or double bond. Accordingly, all cis/trans and E/Z isomers and rotational isomers are expressly included in the present invention.
  • the compounds of this invention may also be represented in multiple tautomeric forms, in such instances, the invention expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented. All such isomeric forms of such compounds are expressly included in the present invention.
  • Optical isomers can be obtained in pure form by standard procedures known to those skilled in the art, and include, but are not limited to, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ.
  • the compounds of this invention include the compounds themselves, as well as their salts and their prodrugs, if applicable.
  • a salt for example, can be formed between an anion and a positively charged substituent (e.g., amino) on a compound described herein. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, and acetate.
  • a salt can also be formed between a cation and a negatively charged substituent (e.g., carboxylate) on a compound described herein.
  • Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion.
  • prodrugs include Ci_ 6 alkyl esters of carboxylic acid groups, which, upon administration to a subject, are capable of providing active compounds.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • pharmaceutically acceptable salt refers to a salt formed by the addition of a pharmaceutically acceptable acid or base to a compound disclosed herein.
  • pharmaceutically acceptable refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient.
  • Suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3- phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thio
  • Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl) 4 salts.
  • alkali metal e.g., sodium
  • alkaline earth metal e.g., magnesium
  • ammonium e.g., ammonium
  • N-(alkyl) 4 salts e.g., ammonium
  • This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • Salt forms of the compounds of any of the formulae herein can be amino acid salts of carboxy groups (e.g. L-arginine, -lysine, -histidine salts).
  • the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the invention.
  • the invention provides compounds which are in a prodrug form.
  • Prodrugs of the compounds described herein are those compounds that undergo chemical changes under physiological conditions to provide the compounds of the invention.
  • prodrugs can be converted to the compounds of the invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
  • Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be more bioavailable by oral administration than the parent drug.
  • the prodrug may also have improved solubility in pharmacological compositions over the parent drug.
  • prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
  • An example, without limitation, of a prodrug would be a compound of the invention which is administered as an ester (the "prodrug"), but then is metabolically hydrolyzed to the carboxylic acid, the active entity.
  • Additional examples include peptidyl derivatives of a compound of the invention.
  • the invention also includes various hydrate and solvate forms of the compounds.
  • the compounds of the invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be encompassed within the scope of the invention.
  • the compounds of present invention can be conveniently prepared in accordance with the procedures outlined in the Examples section, from commercially available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be readily obtained from the relevant scientific literature or from standard textbooks in the field. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Those skilled in the art of organic synthesis will recognize that the nature and order of the synthetic steps presented may be varied for the purpose of optimizing the formation of the compounds described herein.
  • Synthetic chemistry transformations useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R.C. Larock, Comprehensive Organic Transformations, 2d.ed., Wiley- VCH Publishers (1999); P. GM. Wuts and T. W. Greene, Protective Groups in Organic Synthesis, 4th Ed., John Wiley and Sons (2007); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
  • product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy (FT-IR), spectrophotometry (e.g., UV-visible), or mass spectrometry (MS), or by chromatography such as high performance liquid chromatograpy (HPLC) or thin layer chromatography (TLC).
  • spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy (FT-IR), spectrophotometry (e.g., UV-visible), or mass spectrometry (MS), or by chromatography such as high performance liquid chromatograpy (HPLC) or thin layer chromatography (TLC).
  • HPLC high performance liquid chromatograpy
  • TLC thin layer chromatography
  • Preparation of compounds can involve the protection and deprotection of various chemical groups.
  • the need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art.
  • the chemistry of protecting groups can be found, for example, in Greene, et al., Protective Groups in Organic Synthesis, 2d. Ed., Wiley & Sons, 1991, which is incorporated herein by reference in its entirety.
  • Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, i.e., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction can be carried out in one solvent or a mixture of more than one solvents.
  • suitable solvents for a particular reaction step can be selected.
  • An example method includes preparation of the Mosher's ester or amide derivative of the corresponding alcohol or amine, respectively. The absolute configuration of the ester or amide is then determined by proton and/or 19 F NMR spectroscopy.
  • An example method includes fractional recrystallization using a "chiral resolving acid" which is an optically active, salt-forming organic acid.
  • Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids.
  • Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
  • an optically active resolving agent e.g., dinitrobenzoylphenylglycine
  • the compounds of the invention can be prepared, for example, using the reaction pathways and techniques as described below.
  • a series of carbazole 1,2-aminoalcohol compounds of formula 3 may be prepared by the method outlined in Scheme 1.
  • the 9-oxiranylmethyl-9H-carbazole of formula 2 may be prepared from an appropriately substituted carbazole of formula 1 and epichlorohydrin in the presence of a strong base such as sodium hydride.
  • the oxiranyl ring of formula 2 may be opened in the presence of a primary or secondary amine to produce the 1,2-amino alcohol of formula 3.
  • a primary or secondary amine can be, but are not limited to, phenethylamine, 3-phenylallyl amine, and N-substituted piperazines and the like.
  • carbazole 1,2-aminoalcohol compounds of formula 8 may be prepared by the method outlined in Scheme 2.
  • the epoxide of 9-oxiranylmethyl- 9H-carbazole of formula 2 may be opened with a primary amine, H 2 NR 10 , to produce the secondary aminoalcohol of formula 4 and then protected with an amine protecting group (P) such as tert-butoxycarbonyl (Boc) to afford the protected aminoalochol of formula 5.
  • P amine protecting group
  • Boc tert-butoxycarbonyl
  • the hydroxyl group of formula 5 may be alkylated with a strong base such as sodium hydride and an alkylating agent (RX) such as an alkyl halide, tosylate, triflate or mesylate to produce the ether of formula 6.
  • RX alkylating agent
  • RX alkyl halide
  • tosylate triflate or mesylate
  • RX alkylating agent
  • Removal of the amine protecting group in the presence of a suitable acid can provide the desired OR ether compounds of formula 7.
  • reductive alkylation of the secondary amine of formula 7 may be achieved in the presence of an aldehyde and a reducing agent such as sodium cyano borohydride (NaCNBH 3 ) to provide the tertiary 1,2-aminoalcohol of formula 8.
  • a series of substituted indole compounds of formula 11 and 12 may be prepared by the method outlined below in Scheme 3.
  • Compounds of formula 11 may be prepared by the alkylation of an indole of formula 9 with an epoxide A, for example with epichlorohydrin or epibromohydrin, in the presence of a strong base such as potassium hydroxide (KOH) or n-butyllithium (n-BuLi) to produce the oxiranyl indole of formula
  • compounds of formula 12 may be prepared by opening an epoxide B at the less hindered position with the indole nitrogen of formula 9.
  • epoxide derivatives may be prepared by following the methods outlined in Scheme 4.
  • the secondary alcohol of compounds of formula 11 may be oxidized using an oxidizing agent or under Swern-like oxidation conditions to provide the ketone of formula 13 which can further undergo reductive amination to provide the amine of compound 14.
  • Fluorine compounds of formula 16 may be prepared by reaction of the alcohol of formula 11 with a fluorinating agent such as diethylamino sulfur trifluoride (DAST).
  • DAST diethylamino sulfur trifluoride
  • pharmaceutically acceptable carrier refers to a carrier or adjuvant that may be administered to a subject (e.g., a patient), together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
  • compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- ⁇ -tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-pol
  • Cyclodextrins such as OC-, ⁇ -, and ⁇ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- ⁇ -cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
  • compositions for administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules, losenges or the like in the case of solid compositions.
  • the compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
  • the amount administered depends on the compound formulation, route of administration, etc. and is generally empirically determined in routine trials, and variations will necessarily occur depending on the target, the host, and the route of administration, etc.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1, 3, 10 or 30 to about 30, 100, 300 or 1000 mg, according to the particular application.
  • unit dosage forms are packaged in a multipack adapted for sequential use, such as blisterpack, comprising sheets of at least 6, 9 or 12 unit dosage forms.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art.
  • treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small amounts until the optimum effect under the circumstances is reached.
  • the total daily dosage may be divided and administered in portions during the day if desired.
  • Crystalline carbazole (80 g/batch) and the povidone (NF K29/32 at 160 g/batch) are dissolved in methylene chloride (5000 mL).
  • the solution is dried using a suitable solvent spray dryer and the residue reduced to fine particles by grinding.
  • the powder is then passed through a 30 mesh screen and confirmed to be amorphous by x-ray analysis.
  • the solid solution, silicon dioxide and magnesium stearate are mixed in a suitable mixer for 10 minutes.
  • the mixture is compacted using a suitable roller compactor and milled using a suitable mill fitted with 30 mesh screen.
  • Croscarmellose sodium, Pluronic F68 and silicon dioxide are added to the milled mixture and mixed further for 10 minutes.
  • a premix is made with magnesium stearate and equal portions of the mixture. The premix is added to the remainder of the mixture, mixed for 5 minutes and the mixture encapsulated in hard shell gelatin capsule shells.
  • methods for treating e.g., controlling, relieving, ameliorating, alleviating, or slowing the progression of
  • methods for preventing e.g., delaying the onset of or reducing the risk of developing
  • the methods include administering to the subject an effective amount of a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein to the subject.
  • a compound of formula (I) (and/or a compound of any of the other formulae described herein) or a salt (e.g., a pharmaceutically acceptable salt) thereof as defined anywhere herein in the preparation of, or for use as, a medicament for the treatment (e.g., controlling, relieving, ameliorating, alleviating, or slowing the progression of) or prevention (e.g., delaying the onset of or reducing the risk of developing) of one or more diseases, disorders, or conditions caused by, or associated with, aberrant (e.g., insufficient) neurogenesis or exacerbated neuronal cell death is featured.
  • a salt e.g., a pharmaceutically acceptable salt
  • the one or more diseases, disorders, or conditions can include neuropathies, nerve trauma, and neurodegenerative diseases.
  • the one or more diseases, disorders, or conditions can be diseases, disorders, or conditions caused by, or associated with aberrant (e.g., insufficient) neurogenesis (e.g., aberrant hippocampal neurogenesis as is believed to occur in neuropsychiatric diseases) or accelerated death of existing neurons.
  • Examples of the one or more neuropsychiatric and neurodegenerative diseases include, but are not limited to, schizophrenia,major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, posttraumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, and abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine, and cocaine.
  • neuro-active drugs such as alcohol, opiates, methamphetamine, phencyclidine, and cocaine.
  • a resultant promotion of survival, growth, development, function and/or generation of neurons may be detected directly, indirectly or inferentially from an improvement in, or an amelioration of one or more symptoms of the disease or disorder caused by or associated with aberrant neurogenesis or survival of existing neurons.
  • Suitable assays which directly or indirectly detect neural survival, growth, development, function and/or generation are known in the art, including axon regeneration in rat models (e.g. Park et al., Science. 2008 Nov 7; 322:963-6), nerve regeneration in a rabbit facial nerve injury models (e.g. Zhang et al., J Transl Med. 2008 Nov 5;6(1):67); sciatic nerve regeneration in rat models (e.g. Sun et al.,Cell MoI Neurobiol.
  • mice protection against motor neuron degeneration in mice (e.g. Poesen et al. J Neurosci. 2008 Oct 15;28(42):10451-9); rat model of Alzheimer's disease, (e.g. Xuan et al., Neurosci Lett. 2008 Aug 8;440(3):331-5); animal models of depression (e.g. Schmidt et al., e.g. Behav Pharmacol. 2007 Sep;18(5-6):391-418; Krishnan et al. Nature 2008, 455, 894-902); and/or exemplified herein.
  • Parkinson model of Alzheimer's disease e.g. Xuan et al., Neurosci Lett. 2008 Aug 8;440(3):331-5
  • animal models of depression e.g. Schmidt et al., e.g. Behav Pharmacol. 2007 Sep;18(5-6):391-418; Krishnan et al. Nature 2008, 455, 894-902; and/or
  • the compounds and compositions described herein can, for example, be administered orally, parenterally (e.g., subcutaneously, intracutaneously, intravenously, intramuscularly, intraarticularly, intraarterially, intrasynovially, intrasternally, intrathecally, intralesionally and by intracranial injection or infusion techniques), by inhalation spray, topically, rectally, nasally, buccally, vaginally, via an implanted reservoir, by injection, subdermally, intraperitoneally, transmucosally, or in an ophthalmic preparation, with a dosage ranging from about 0.01 mg/kg to about 1000 mg/kg, (e.g., from about 0.01 to about 100 mg/kg, from about 0.1 to about 100 mg/kg, from about 1 to about 100 mg/kg, from about 1 to about 10 mg/kg) every 4 to 120 hours, or according to the requirements of the particular drug.
  • parenterally e.g., subcutaneously, intracutaneously, intravenously, intramus
  • compositions are administered by oral administration or administration by injection.
  • the methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • the compounds described herein can be coadministered with one or more other threapeutic agents.
  • the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention (e.g., sequentially, e.g., on different overlapping schedules with the administration of one or more compounds of formula (I) (including any subgenera or specific compounds thereof)).
  • these agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
  • these agents can be given as a separate dose that is administered at about the same time that one or more compounds of formula (I) (including any subgenera or specific compounds thereof) are administered (e.g., simultaneously with the administration of one or more compounds of formula (I) (including any subgenera or specific compounds thereof)).
  • compositions of this invention include a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent can be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
  • compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3- butanediol.
  • suitable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions.
  • surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • compositions of this invention may also be administered in the form of suppositories for rectal administration.
  • These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
  • suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
  • Topical administration of the compositions of this invention is useful when the desired treatment involves areas or organs readily accessible by topical application.
  • the composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
  • the composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation.
  • topical administration of the compounds and compositions described herein may be presented in the form of an aerosol, a semi-solid pharmaceutical composition, a powder, or a solution.
  • a semi-solid composition is meant an ointment, cream, salve, jelly, or other pharmaceutical composition of substantially similar consistency suitable for application to the skin. Examples of semi-solid compositions are given in Chapter 17 of The Theory and Practice of Industrial Pharmacy, Lachman, Lieberman and Kanig, published by Lea and Febiger (1970) and in Remington's Pharmaceutical Sciences, 21st Edition (2005) published by Mack Publishing Company, which is incorporated herein by reference in its entirety.
  • Topically-transdermal patches are also included in this invention. Also within the invention is a patch to deliver active chemotherapeutic combinations herein.
  • a patch includes a material layer (e.g., polymeric, cloth, gauze, bandage) and the compound of the formulae herein as delineated herein. One side of the material layer can have a protective layer adhered to it to resist passage of the compounds or compositions.
  • the patch can additionally include an adhesive to hold the patch in place on a subject.
  • An adhesive is a composition, including those of either natural or synthetic origin, that when contacted with the skin of a subject, temporarily adheres to the skin. It can be water resistant. The adhesive can be placed on the patch to hold it in contact with the skin of the subject for an extended period of time.
  • the adhesive can be made of a tackiness, or adhesive strength, such that it holds the device in place subject to incidental contact, however, upon an affirmative act (e.g., ripping, peeling, or other intentional removal) the adhesive gives way to the external pressure placed on the device or the adhesive itself, and allows for breaking of the adhesion contact.
  • the adhesive can be pressure sensitive, that is, it can allow for positioning of the adhesive (and the device to be adhered to the skin) against the skin by the application of pressure (e.g., pushing, rubbing,) on the adhesive or device.
  • compositions of this invention may be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • a composition having the compound of the formulae herein and an additional agent can be administered using any of the routes of administration described herein.
  • a composition having the compound of the formulae herein and an additional agent can be administered using an implantable device.
  • Implantable devices and related technology are known in the art and are useful as delivery systems where a continuous, or timed- release delivery of compounds or compositions delineated herein is desired. Additionally, the implantable device delivery system is useful for targeting specific points of compound or composition delivery (e.g., localized sites, organs). Negrin et al., Biomaterials, 22(6):563 (2001). Timed-release technology involving alternate delivery methods can also be used in this invention. For example, timed-release formulations based on polymer technologies, sustained-release techniques and encapsulation techniques (e.g., polymeric, liposomal) can also be used for delivery of the compounds and compositions delineated herein.
  • Example Ia and Ib S- and /M-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3- methoxyphenylamino)-propan-2-ol
  • m-Anisidine (1.0 niL, 8.95 mmol) was added to a suspension of epoxide (3.02 g, 7.92 mmol) in cyclohexane (73 mL).
  • BiCl 3 (0.657 g, 2.08 mmol) was added and the mixture was heated to reflux overnight.
  • Step 3 Synthesis of l-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3- methoxyphenylamino)propan-2-yl 3,3,3-trifluoro-2-methoxy-2-phenylpropanoate
  • ester 1 from example 3 (0.011 g, 0.015 mmol) was dissolved in degassed Et 2 O (0.150 mL) and cooled to 0 0 C.
  • Lithium aluminum hydride (IM in THF, 0.018 mL, 0.018 mmol) was added via syringe and the reaction was stirred for 20 min.
  • TLC Upon completion by TLC the reaction was quenched by the addition of MeOH and stirred for 45 min. The mixture was partitioned between EtOAc and H 2 O.
  • Example 2 was prepared following Representative Procedure 2, except with a reaction time of 2 days at 80 0 C. The crude product was used without further purification.
  • Benzenethiol (30 ⁇ l, 0.29 mmol) was added to a solution of 3,6-dibromo-9- (oxiran-2-ylmethyl)-9H-carbazole (101.6 mg, 0.27 mmol) in 5.0 ml MeOH at r.t.
  • the reaction mixture was heated to 80 0 C and stirred overnight at the same temperature.
  • the reaction was monitored by lc/ms for the consumption of SM.
  • the reaction was cooled, diluted with ethyl acetate and washed with water and brine. The organic layer was dried over Na 2 SO 4 , filtered and condensed.
  • JN- 131-168 was prepared from dibromocarbazole and phenoxymethyloxirane in 61% yield.
  • the reaction vessel was purged with nitrogen, sealed and heated under microwave radiation to 150 0 C for 9 minutes.
  • the reaction was monitored by lc/ms and all SM had been consumed.
  • the heterogeneous solution was filtered under vacuum to yield a white solid.
  • the crude product was used without purification.
  • Methyl chloroformate (10 ⁇ l, 0.13 mmol) was added to a stirring solution of jn- 128-186 (55.0 mg, 0.11 mmol) and indium powder (3.5 mg, 0.030 mmol) in acetonitrile (3.0 ml), and the reaction mixture was stirred overnight at r.t. An additional 3.1 mg (0.027 mmol) of indium and 20 ⁇ l (2.6 eq.) of methyl chloroformate were added. After several hours, the reaction was diluted with ethyl actetate, and washed with water and then brine. The organic layer was dried over Na 2 SO 4 , filtered and concentrated.
  • the methyl carbonate was purified via flash chromatography in 20-40% ethyl acetate/hexanes. Sodium methoxide (3.0 ml) was added to a solution of carbonate (21.3 mg, 0.038 mmol) and methanol (1.0 ml). After an hour at ambient temperature the solution was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and brine and condensed.
  • Example 6b was synthesized in 71% yield.
  • Trietheylamine (1.65 ml, 11.8 mmol ) was added to a stirring solution of l-(3,6- dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol (1.02 g, 2.02 mmol) in DMSO (21 ml). The solution was stirred for 30 minutes before addition of sulfur trioxide pyridine complex (0.659 g, 4.14 mmol). After stirring overnight, additional triethylamine (1.0 ml, 7.17 mmol) was added, followed by sulfur trioxide pyridine complex (0.663 mg, 4.17 mmol) an hour later.
  • Example 14 was prepared in 74% yield.
  • Example 15 was prepared from 3-Bromo- 6-methyl-9-(oxiran-2-ylmethyl)-9H-carbazole in 41% yield.
  • Step 2 Synthesi of l-(3,6-Dichloro-9H-carbazol-9-yl)-3-(3- methoxyphenylamino)propan-2-ol
  • Step 3 Synthesis of ' 1 -(5-bromo-2,3-dimethyl-l H-indol-1 -yl)-3-(phenylamino)propan-2- ol
  • Example 14 was prepared in 14% yield.
  • 3,6-Dibromocarbazole (0.050 g, 0.154 mmol) was dissolved in DMF (1.5 niL) and cooled to 0 0 C. NaH (60% dispersion in mineral oil, 0.007 g, 0.169 mmol) was added and the reaction was stirred for 45 min at 0 0 C. 3,6-Dibromo-9-(oxiran-2- ylmethyl)-9H-carbazole (0.059 g, 0.154 mmol) was added and the reaction was stirred at ambient temperature for 24 h. Upon consumption of the starting material by TLC, the reaction was partitioned between EtOAc and H 2 O.
  • Example 16 was prepared in 48% yield.
  • Ethyl 8-methyl-3,4-dihydro-lH-pyrido[4,3-b]indole-2(5H)-carboxylate (0.025 g, 0.097 mmol) was dissolved in anhydrous degassed T ⁇ F and was cooled to -78 0 C. A solution of w-BuLi (0.082 rnL, 1.78 M in hexanes) was added dropwise and the reaction was stirred at -78 0 C for 30 min. Epibromohydrin (0.016 rnL, 0.194 mmol) was added and the reaction was allowed to warm slowly to ambient temperature.
  • LiBr (0.001 g, 0.010 mmol) and m-anisidine (0.011 rnL, 0.102 mmol) were added to ethyl 8-Methyl-5-(oxiran-2-ylmethyl)-3,4- dihydro-lH-pyrido[4,3-b]indole-2(5H)-carboxylate (0.032 g, 0.102 mmol) and stirred vigorously at ambient temperature overnight.
  • Example 19 was isolated as a white solid in 31% yield.
  • N-(3-(3,6-dibromo-9H-carbazol-9-yl)propyl)-2-nitro-N- phenylbenzenesulfonamide (0.0378g, 0.0588mmol, lequiv), cesium carbonate (0.0574g, 0.176 mmol, 3equiv) and benzenethiol (0.0194g, 0.176 mmol) were mixed in ImL anhydrous THF. The mixture was stirred at room temperature for 3 hours. THF was removed under vacuum and the residue was purified by silica gel chromatography using Hexanes/EtOAc to afford 0.0164g colorless oil as product, yield 60.9%.
  • Example 25 was synthesized using a similar synthetic procedure analogous to Representative Procedure 2.
  • Example 28 was prepared from dibromocarbazole and methoxymethyloxirane
  • Example 29 was prepared from dibromocarbazole and 2-phenethyloxirane.
  • Example 30 was prepared from dibromocarbazole and l-(oxiran-2-ylmethyl)-lH-indole.
  • Example 31 was synthesized using a similar synthetic procedure analogous to Representative Procedure 2.
  • Example 32 was synthesized using a similar synthetic procedure analogous to Representative Procedure 2.
  • Example 33 l- ⁇ o-dibromo ⁇ H-carbazol ⁇ -y ⁇ -S- ⁇ S-dimethyl-lH-pyrazol-l- yl)propan-2-ol
  • Example 33 was synthesized using a similar synthetic procedure analogous to Representative Procedure 2.
  • Example 36 was synthesized using a similar synthetic procedure analogous to Representative Procedure 2.
  • Example 62 Compound using a known procedure (Alexander, M.D., Burkart, M.D., Leonard, M.S., Portonovo, P., Liang, B., Ding, X., Joullie, M.M., Gulledge, B.M., Aggen, J.B., Chamberlin, A.R., Sandler, J., Fenical, W., Cui, J., Gharpure, S. J., Polosukhin, A., Zhang, H-R., Evans, P.
  • Example 39 was synthesized following Representative Procedure 1 and Example
  • Example 40 was synthesized using a similar synthetic procedure analogous to Representative Procedure 2.
  • Example 41 was synthesized using a similar synthetic procedure analogous to
  • Example 42 was synthesized using a similar synthetic procedure analogous to Representative Procedure 2.
  • Example 43 was synthesized using a similar synthetic procedure analogous to Representative Procedure 2 and Example 6a.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet général la stimulation de la neurogenèse (par exemple, la neurogenèse post-natale, par exemple, la neurogenèse post-natale hippocampique) et la protection contre la mort des cellules neuronales.
EP10711784.8A 2009-01-09 2010-01-11 Composés pro-neurogéniques Not-in-force EP2385829B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14375509P 2009-01-09 2009-01-09
PCT/US2010/020681 WO2010081115A1 (fr) 2009-01-09 2010-01-11 Composés pro-neurogéniques

Publications (2)

Publication Number Publication Date
EP2385829A1 true EP2385829A1 (fr) 2011-11-16
EP2385829B1 EP2385829B1 (fr) 2018-08-01

Family

ID=42224725

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10711784.8A Not-in-force EP2385829B1 (fr) 2009-01-09 2010-01-11 Composés pro-neurogéniques

Country Status (9)

Country Link
US (4) US8604074B2 (fr)
EP (1) EP2385829B1 (fr)
JP (1) JP5766614B2 (fr)
CN (2) CN102405043B (fr)
AU (1) AU2010203356B2 (fr)
BR (1) BRPI1006825A2 (fr)
CA (1) CA2748813C (fr)
IL (1) IL213992A (fr)
WO (1) WO2010081115A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8546381B2 (en) 2008-03-24 2013-10-01 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
CN104387382A (zh) 2008-03-24 2015-03-04 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
AR073924A1 (es) 2008-10-31 2010-12-09 Medivation Technologies Inc Azepino[4, 5-b]indoles, una composicion farmaceutica y kits que los comprenden y su uso en la modulacion de un receptor de histamina.
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
CN102405043B (zh) 2009-01-09 2017-08-22 得克萨斯州大学系统董事会 前神经原性化合物
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
BRPI1006602A2 (pt) 2009-04-29 2019-01-15 Medivation Technologies Inc composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
WO2011038163A1 (fr) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles et leurs méthodes d'utilisation
JP5869484B2 (ja) 2009-09-23 2016-02-24 メディベイション テクノロジーズ， インコーポレイテッド 架橋複素環化合物およびその使用
EP2480078A4 (fr) 2009-09-23 2013-03-06 Medivation Technologies Inc Pyrido[4,3-b]indoles et leurs méthodes d'utilisation
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (fr) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Dérivés de pyrido[4,3-b]indole et de pyrido[3,4-b]indole tétracycliques condensés et leurs procédés d'utilisation
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
CN103415289B (zh) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物
WO2012112964A2 (fr) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Dérivés de pyrido[4,3-b]indole et de pyrido[3,4-b]indole et procédés d'utilisation
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
JP2014505737A (ja) 2011-02-18 2014-03-06 メディベイション テクノロジーズ， インコーポレイテッド 糖尿病を処置する化合物および方法
US20140155384A1 (en) 2011-02-18 2014-06-05 Medivation Technologies, Inc. Compounds and methods of treating diabetes
AU2012338362B2 (en) 2011-11-15 2017-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof
NZ701702A (en) 2012-05-11 2017-07-28 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
CN108329253A (zh) * 2012-08-24 2018-07-27 得克萨斯州大学系统董事会 前神经原性化合物
AU2013305591B2 (en) * 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9353078B2 (en) * 2013-10-01 2016-05-31 New York University Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof
WO2015070237A1 (fr) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Produits chimiques neuroprotecteurs et leurs procédés d'identification et d'utilisation
WO2015070234A2 (fr) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Composés neuroprotecteurs et leur utilisation
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
PT3288637T (pt) 2015-04-28 2022-10-11 Newsouth Innovations Pty Ltd Visar nad+ para tratar comprometimento cognitivo, neuropatias e inatividade induzidos por quimioterapia e radioterapia
CN104974141B (zh) * 2015-07-27 2017-04-05 西南大学 咔唑四唑类衍生物及其制备方法和应用
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs
WO2017161261A1 (fr) 2016-03-18 2017-09-21 University Of South Florida Procédés et utilisations d'activateurs de nampt pour le traitement du diabète, de maladies cardiovasculaires et de leurs symptômes
AU2020229779A1 (en) 2019-02-27 2021-09-09 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
CN113402444B (zh) * 2021-06-17 2024-05-03 上海欧坤生物医药科技有限公司 一种咔唑类化合物及其在制备治疗脂肪肝及2型糖尿病等代谢相关疾病药物中的应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE537690A (fr) 1954-07-01
US3518250A (en) * 1965-12-17 1970-06-30 Ibm Substitution of imino-heterocyclic compounds
US3409628A (en) * 1966-05-12 1968-11-05 Hoffmann La Roche 5-(3-pyridylethyl)pyridoindole derivatives
US4495281A (en) 1982-10-21 1985-01-22 Miles Laboratories, Inc. Tricyclic antidepressant drug immunogens, antibodies, labeled conjugates, and related derivatives
JPH04217657A (ja) 1990-10-19 1992-08-07 Toyo Gosei Kogyo Kk ４‐（ｎ‐アリールカルバモイルアルキルチオ）フェノール系化合物及びこれを用いた感熱記録材料
JP2684252B2 (ja) * 1991-03-08 1997-12-03 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
US5234923A (en) 1991-12-16 1993-08-10 E. R. Squibb & Sons, Inc. Substitute indole and benzimidazole derivatives
JPH11504905A (ja) 1995-05-05 1999-05-11 ノボ ノルディスク アクティーゼルスカブ 新規複素環の化学
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
WO1998015546A1 (fr) 1996-10-04 1998-04-16 Novo Nordisk A/S Composes azaheterocycliques n-substitues
US6468996B1 (en) * 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
EP1123279A1 (fr) 1998-10-21 2001-08-16 Novo Nordisk A/S Nouveaux composes, preparation et utilisation correspondantes
EP1192178A2 (fr) 1999-06-21 2002-04-03 Eli Lilly And Company Rufomycines et leurs derives utiles comme inhibiteurs de la proteine-1 associee a la resistance aux antibiotiques (mrp-1)
MY125942A (en) * 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
EP1094063A1 (fr) * 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Pipérazinylalkyl)carbazoles comme modulateurs de Bax
GB9925880D0 (en) 1999-11-01 1999-12-29 British Tech Group Int B-Carboline derivatives
CA2397575A1 (fr) * 2000-01-13 2001-07-19 Tularik Inc. Agents antibacteriens
EP1125925A1 (fr) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Dérivés amines pour le traitement de l'apoptose
US6340548B1 (en) 2000-03-16 2002-01-22 Imation Corp. Organophotoreceptors for electrophotography featuring novel charge transport compounds
PT1268418E (pt) * 2000-03-27 2006-08-31 Applied Research Systems Derivados da pirrolidina farmacologicamente activos com inibidores bax
US20020173549A1 (en) 2000-11-08 2002-11-21 Wurtman Richard J. Compositions and methods for treatment of mild cognitive impairment
WO2002060867A2 (fr) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Derives de carbazole et leur utilisation en tant qu'inhibiteurs d'heparanase
US20030092869A1 (en) 2001-07-13 2003-05-15 Luping Yu Novel nonlinear optical polymers
ES2250689T3 (es) * 2001-08-08 2006-04-16 PHARMACIA & UPJOHN COMPANY LLC 1h-pirido(4,3-b)indoles terapeuticos.
US6835513B2 (en) * 2002-03-28 2004-12-28 Samsung Electronic Co., Ltd. Carbazole based charge transport compounds
US6864025B2 (en) * 2002-03-28 2005-03-08 Samsung Electronics Co., Ltd. Sulfonyldiphenylene-based charge transport compositions
MXPA04010555A (es) 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
BR0316771A (pt) 2002-12-10 2005-10-25 Virochem Pharma Inc Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
CN100503607C (zh) 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
WO2005037845A1 (fr) 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Compositions de benzothiazole et de thiazole'5,5-b!pyridine et leur utilisation comme inhibiteurs de l'ubiquitine ligase
GB0324551D0 (en) * 2003-10-21 2003-11-26 Karobio Ab Novel compounds
WO2005056522A2 (fr) 2003-12-04 2005-06-23 National Health Research Institutes Composes indoles
RU2283108C2 (ru) 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20070196395A1 (en) * 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
EP1713501B1 (fr) 2004-01-29 2008-01-16 Cellzome Ag Traitement de maladies neurodegeneratives au moyen de gpr49
WO2005085227A1 (fr) * 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibiteurs de l'activite de la proteine kinase b (akt)
US20050244674A1 (en) 2004-04-28 2005-11-03 Jsr Corporation Phosphorescent polymer and production process thereof, organic electroluminescence device, and metal conplex-containing compond and production process thereof
US7445877B2 (en) * 2004-06-10 2008-11-04 Samsung Electronics Co., Ltd. Charge transport materials having a central disulfane linkage
CN1738069A (zh) * 2004-08-17 2006-02-22 国际商业机器公司 其电极具有增强注入特性的电子器件制造方法和电子器件
WO2006041624A2 (fr) 2004-09-20 2006-04-20 Washington University Systemes de biosynthese de nad
CA2583622A1 (fr) 2004-10-13 2006-04-27 Merck & Co., Inc. Compositions ophtalmiques de traitement de l'hypertension oculaire
US7834063B2 (en) * 2004-10-13 2010-11-16 Glaxosmithkline Llc Benzonitryl and nitrobenzyl derivatives that modulate androgen receptors
WO2006077954A1 (fr) * 2005-01-21 2006-07-27 Kyowa Hakko Kogyo Co., Ltd. Remede pour maladie neurologique
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
WO2006113367A2 (fr) 2005-04-15 2006-10-26 Tgen Methodes, composes et compositions a activite anticancereuse selective relative au genotype
WO2007008541A2 (fr) 2005-07-08 2007-01-18 Kalypsys, Inc. Modificateurs d'absorption de cholesterol cellulaire
CA2624731A1 (fr) 2005-10-04 2007-04-12 Medivation, Inc. Procedes et compositions de traitement de la maladie d'huntington
US7438916B2 (en) * 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
DK1957086T3 (en) 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
RU2448703C2 (ru) 2005-11-23 2012-04-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Онкогенное ras-специфичное цитотоксическое соединение и способы его применения
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
WO2007079239A2 (fr) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Composes bicycliques a base d'azote en tant que modulateurs de recepteur de ghreline et leurs utilisations
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
US20070203236A1 (en) * 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
RU2338537C2 (ru) 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20090088449A1 (en) * 2006-02-07 2009-04-02 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
JP2007223916A (ja) * 2006-02-21 2007-09-06 Institute Of Physical & Chemical Research 抗菌剤
WO2007115231A2 (fr) * 2006-03-30 2007-10-11 Chemocentryx, Inc. Modulateurs de cxcr4
JP2009536669A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
RU2008150624A (ru) 2006-05-22 2010-06-27 Ванда Фармасьютиклз, Инк. (Us) Лечение депрессивных расстройств
WO2008021745A2 (fr) 2006-08-16 2008-02-21 Itherx Pharmaceuticals, Inc. Inhibiteurs de la pénétration du virus de l'hépatite c
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
RU2338745C1 (ru) 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2334747C1 (ru) 2007-04-05 2008-09-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
JP5540701B2 (ja) 2007-06-21 2014-07-02 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子材料
CA2700173C (fr) 2007-09-25 2016-10-11 Topotarget Uk Limited Procedes de synthese de certains composes d'acide hydroxamique
CN101139347B (zh) 2007-10-15 2010-11-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
CN101429198B (zh) 2007-11-09 2013-10-23 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物及其应用
EP2236511A4 (fr) 2007-12-21 2011-04-13 Alla Chem Llc Ligands d'alpha-adrénorécepteurs, de récepteurs de dopamine, de l'histamine, d'imidazoline et de sérotonine ainsi que leurs procédés d'utilisation
CA2709784A1 (fr) * 2007-12-21 2009-07-09 University Of Rochester Procede permettant de modifier la duree de vie d'organismes eucaryotes
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US9079999B2 (en) * 2008-02-26 2015-07-14 Rigoberto Advincula Methods for preparing polymer coatings by electrochemical grafting of polymer brushes, compositions prepared thereby and compositions for preparing the coatings
CN104387382A (zh) 2008-03-24 2015-03-04 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
US7989127B2 (en) 2008-04-30 2011-08-02 Xerox Corporation Carbazole containing charge transport layer photoconductors
BRPI0919564A2 (pt) * 2008-10-22 2019-09-24 Genentech Inc modulação da degeneração do axônio
AR073924A1 (es) 2008-10-31 2010-12-09 Medivation Technologies Inc Azepino[4, 5-b]indoles, una composicion farmaceutica y kits que los comprenden y su uso en la modulacion de un receptor de histamina.
AR073923A1 (es) 2008-10-31 2010-12-09 Medivation Technologies Inc Pirido( 4,3-b) indoles que contienen restos rigidos
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102405043B (zh) 2009-01-09 2017-08-22 得克萨斯州大学系统董事会 前神经原性化合物
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102480956B (zh) 2009-04-29 2015-04-08 梅迪维新技术公司 吡啶并[4,3-b]吲哚类和使用方法
US8763653B2 (en) 2009-08-06 2014-07-01 Harro Höfliger Verpackungsmaschinen GmbH Filling assembly for metering powder and method for operating such a filling assembly
EP2480079A4 (fr) 2009-09-23 2015-04-08 Medivation Technologies Inc Pyrido(3,4-b)indoles et leurs méthodes d'utilisation
US8927538B2 (en) 2010-03-22 2015-01-06 Council Of Scientific & Industrial Research Carbazole linked pyrrolo[2,1-c][1,4]benzodiazefine hybrids as potential anticancer agents and process for the preparation thereof
CN103415289B (zh) * 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物
WO2012067963A1 (fr) 2010-11-15 2012-05-24 Abbott Laboratories Inhibiteurs de nampt
CA2850836A1 (fr) 2011-10-15 2013-04-18 Genentech, Inc. Procedes d'utilisation d'antagonistes de scd1
CN108329253A (zh) 2012-08-24 2018-07-27 得克萨斯州大学系统董事会 前神经原性化合物
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015035051A1 (fr) 2013-09-04 2015-03-12 Board Of Regents Of The University Of Texas System Procédés et compositions pour une cancérothérapie sélective et ciblée
WO2015070234A2 (fr) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Composés neuroprotecteurs et leur utilisation
WO2015070237A1 (fr) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Produits chimiques neuroprotecteurs et leurs procédés d'identification et d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010081115A1 *

Also Published As

Publication number Publication date
BRPI1006825A2 (pt) 2019-04-24
CN102405043B (zh) 2017-08-22
CN107595841A (zh) 2018-01-19
CA2748813C (fr) 2018-07-10
JP2012515166A (ja) 2012-07-05
US20140094480A1 (en) 2014-04-03
WO2010081115A1 (fr) 2010-07-15
AU2010203356A1 (en) 2011-08-04
US20150057301A1 (en) 2015-02-26
US20160206594A1 (en) 2016-07-21
US9278923B2 (en) 2016-03-08
IL213992A0 (en) 2011-08-31
EP2385829B1 (fr) 2018-08-01
CA2748813A1 (fr) 2010-07-15
US10172827B2 (en) 2019-01-08
US9156787B2 (en) 2015-10-13
US8604074B2 (en) 2013-12-10
US20110015217A1 (en) 2011-01-20
CN102405043A (zh) 2012-04-04
JP5766614B2 (ja) 2015-08-19
AU2010203356B2 (en) 2015-11-26
IL213992A (en) 2016-04-21

Similar Documents

Publication Publication Date Title
US10172827B2 (en) Pro-neurogenic compounds
US9446042B2 (en) Pro-neurogenic compounds
US9884820B2 (en) Pro-neurogenic compounds
US8735440B2 (en) Methods for treating amyotrophic lateral sclerosis using pro-neurogenic compounds
AU2012388221A1 (en) Pro-neurogenic compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110728

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DE BRABANDER, JEF

Inventor name: READY, JOSEPH, M.

Inventor name: PIEPER, ANDREW, A.

Inventor name: MCKNIGHT, STEVEN, L.

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 405/12 20060101ALI20171205BHEP

Ipc: C07D 209/88 20060101ALI20171205BHEP

Ipc: C07D 401/12 20060101ALI20171205BHEP

Ipc: C07D 471/04 20060101ALI20171205BHEP

Ipc: C07D 413/06 20060101ALI20171205BHEP

Ipc: A61K 31/44 20060101ALI20171205BHEP

Ipc: A61K 31/404 20060101ALI20171205BHEP

Ipc: C07D 401/06 20060101ALI20171205BHEP

Ipc: C07D 403/06 20060101ALI20171205BHEP

Ipc: A61K 31/415 20060101ALI20171205BHEP

Ipc: A61K 31/4192 20060101ALI20171205BHEP

Ipc: C07D 403/12 20060101ALI20171205BHEP

Ipc: A61K 31/00 20060101AFI20171205BHEP

Ipc: C07D 209/86 20060101ALI20171205BHEP

Ipc: A61K 31/506 20060101ALI20171205BHEP

Ipc: A61K 31/422 20060101ALI20171205BHEP

Ipc: A61K 31/4439 20060101ALI20171205BHEP

Ipc: C07D 209/08 20060101ALI20171205BHEP

Ipc: A61K 31/437 20060101ALI20171205BHEP

Ipc: A61K 31/403 20060101ALI20171205BHEP

Ipc: A61K 31/4155 20060101ALI20171205BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602010052324

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031000000

Ipc: A61P0025160000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/437 20060101ALI20180208BHEP

Ipc: A61K 31/44 20060101ALI20180208BHEP

Ipc: A61K 31/403 20060101ALI20180208BHEP

Ipc: A61P 25/28 20060101ALI20180208BHEP

Ipc: A61P 25/18 20060101ALI20180208BHEP

Ipc: A61P 25/16 20060101AFI20180208BHEP

Ipc: A61K 31/415 20060101ALI20180208BHEP

Ipc: A61K 31/506 20060101ALI20180208BHEP

INTG Intention to grant announced

Effective date: 20180221

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1023613

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180815

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010052324

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180801

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1023613

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181101

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181102

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181101

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181201

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20190124

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20190221

Year of fee payment: 17

Ref country code: MC

Payment date: 20190129

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010052324

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20190116

Year of fee payment: 10

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20190117

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20191216

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20191231

Year of fee payment: 11

Ref country code: GB

Payment date: 20200102

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20200116

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200131

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010052324

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210803

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210131

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210111

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200111

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180801